

<b>PHP_2.04.146</b>		<b>Gene Expression Profiling for Cutaneous Melanoma</b>	
<b>Original Policy Date:</b>	March 1, 2026	<b>Effective Date:</b>	March 1, 2026
<b>Section:</b>	2.0 Medicine	<b>Page:</b>	Page 1 of 422

**State Guidelines**

Applicable Medi-Cal guidelines as of the publication of this policy (**this guideline supersedes the criteria in the Policy Statement section below**):

- I. Department of Managed Health Care (DMHC) All Plan Letter (APL) Guideline:
  - N/A
- II. Department of Health Care Services (DHCS) Provider Manual Guideline:
  - [TAR and Non-Standard Benefits List: Codes 0001M thru 0999U \(tar and non cd0\)](#)
  - [TAR and Non-Standard Benefits List: Codes 80000 thru 89999 \(tar and non cd8\)](#)
- III. Department of Health Care Services (DHCS) All Plan Letter (APL) Guideline:
  - [APL 22-010](#) – Cancer Biomarker Testing

Below is an excerpt of the guideline language. Please refer to the specific All Plan Letter in the link above for the complete guideline.

For the purposes of this APL, “Biomarker test” is defined as a diagnostic test, single or multigene, of an individual’s biospecimen, such as tissue, blood, or other bodily fluids, for DNA or RNA alterations, including phenotypic characteristics of a malignancy, to identify an individual with a subtype of cancer, in order to guide treatment. Biomarkers, also called tumor markers, are substances found in higher-than-normal levels in the cancer itself, or in blood, urine, or tissues of some individuals with cancer. Biomarkers can determine the likelihood some types of cancer will spread. They can also help doctors choose the best treatment.

Medi-Cal managed care health plans (MCPs) are required to cover medically necessary biomarker testing for members with:

- Advanced or metastatic stage 3 or 4 cancer.
- Cancer progression or recurrence in the member with advanced or metastatic stage 3 or 4 cancer.

MCPs are prohibited from imposing prior authorization requirements on biomarker testing that is associated with a federal Food and Drug Administration (FDA)-approved therapy for advanced or metastatic stage 3 or 4 cancer. If the biomarker test is not associated with an FDA-approved cancer therapy for advanced or metastatic stage 3 or 4 cancer, MCPs may still require prior authorization for such testing.

## Policy Statement

Any criteria that are not specifically addressed in the above APL, please refer to the criteria below.

- I. Gene expression testing, including but not limited to the Pigmented Lesion Assay, in the evaluation of individuals with suspicious pigmented lesions is considered **investigational**.
- II. Gene expression testing, including but not limited to the myPath Melanoma test, in the evaluation of individuals with melanocytic lesions with indeterminate histopathologic features is considered **investigational**.
- III. Gene expression testing, including but not limited to DecisionDx-Melanoma, in the evaluation of individuals with cutaneous melanoma is considered **investigational** for all indications.

Note: For individuals enrolled in health plans subject to the Biomarker Testing Law (Health & Safety Code Section 1367.667 and the Insurance Code Section 10123.209), Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) may also apply. Please refer to the [Medicare National and Local Coverage](#) section of this policy, to [MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma](#), and to [MoIDX: Melanoma Risk Stratification Molecular Testing](#) for reference.

## Policy Guidelines

### Genetic Counseling

Experts recommend formal genetic counseling for individuals who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some individuals; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

### Coding

See the [Codes table](#) for details.

## Description

Laboratory tests have been developed that detect the expression of different genes in pigmented lesions or melanoma tumor tissue. Test results may help providers and patients decide whether to biopsy suspicious pigmented lesions, aid in the diagnosis of lesions with indeterminate histopathologic lesions or determine whether to perform sentinel lymph node biopsy in patients diagnosed with stage I or II cutaneous melanoma. This report summarizes the evidence of 3 tests.

### Summary of Evidence

For individuals with suspicious pigmented lesions (based on ABCDE and/or ugly duckling criteria) being considered for biopsy who receive gene expression profiling (GEP) with the DermTech Pigmented Lesion Assay to determine which lesions should proceed to biopsy, the evidence includes observational studies. Relevant outcomes are overall survival, disease-specific survival, validity, and resource utilization. The Pigmented Lesion Assay has 4 clinical validity studies with many methodologic and reporting limitations. Therefore, performance characteristics are not well-characterized. Also, the test has not been compared with dermoscopy, another tool frequently used

to make biopsy decisions. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have melanocytic lesions with indeterminate histopathologic features who receive GEP with the myPath Melanoma test added to histopathology to aid in the diagnosis of melanoma, the evidence includes observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, and treatment-related morbidity. The myPath test has 2 clinical validity studies including long-term follow-up for metastasis as the reference standard. In 1 study, it is not clear whether the study population included lesions that were indeterminate following histopathology. The second study focused on indeterminate lesions but had limitations including a retrospective design and less than 5-year follow-up in 31% of cases. Therefore, performance characteristics are not well-characterized. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with American Joint Committee on Cancer (AJCC) stage I to III cutaneous melanoma who receive GEP with the DecisionDx-Melanoma test to inform management decisions regarding surveillance, the evidence includes retrospective and prospective observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, resource utilization, and treatment-related morbidity. The DecisionDx-Melanoma test has 3 independent clinical validity studies that have reported 5-year recurrence-free survival (RFS) in AJCC stage I or II patients. Gerami et al (2015) reported RFS rates of 37% for DecisionDx class 2 (high-risk) in patients in AJCC stage I and II patients combined. Zager et al (2018) reported RFS rates of 85% (95% confidence interval [CI], 74% to 97%) for DecisionDx class 2 patients in AJCC stage I and 55% (95% CI, 44% to 69%) for DecisionDx class 2 in AJCC stage II disease. The RFS does not appear to be well-characterized as evidenced by the variation in estimates across studies. This indication is to 'rule-in' patients for enhanced surveillance; therefore, specificity and positive predictive value (PPV) are key performance characteristics. In Zager et al (2018) and Greenhaw et al (2018) the specificities were 71% and 87%, respectively, while the PPV were 48% and 24%, respectively. The PPV suggests that the majority of patients identified as high-risk by the DecisionDx test would not develop metastasis and would be unnecessarily subjected to additional surveillance. Greenhaw et al (2018) also reported that in 219 AJCC stage I patients, 201 had DecisionDx class 1 (low-risk) scores and 18 had DecisionDx class 2 (high-risk) scores. The only metastasis in stage I patients occurred in a patient with a DecisionDx class 1 score. Therefore, none of their stage I patients benefited from DecisionDx testing but 18 (8%) were incorrectly identified as high-risk for metastasis and could have received unnecessary surveillance. Five-year RFS data are not available for the subgroup of patients for whom a 'rule-out' test would be relevant (class IIB through III). There is no evidence that changes to the frequency and methods for surveillance improve outcomes. Given that the evidence is insufficient to demonstrate test performance and there is no evidence that changes in surveillance improve outcomes, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with AJCC stage I or II cutaneous melanoma who receive GEP with the DecisionDx-Melanoma test to inform management decisions regarding adjuvant therapy, the evidence includes retrospective and prospective observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, resource utilization and treatment-related morbidity. The DecisionDx-Melanoma test has 3 independent clinical validity studies that have reported 5-year RFS in AJCC stage I or II patients. Gerami et al (2015) reported RFS rates of 37% for DecisionDx class 2 (high-risk) in patients in AJCC stage I and II patients combined. Zager et al (2018) reported RFS rates of 85% (95% CI, 74% to 97%) for DecisionDx class 2 patients in AJCC stage I and 55% (95% CI, 44% to 69%) for DecisionDx class 2 in AJCC stage II disease. RFS does not appear to be

well-characterized as evidenced by the variation in estimates across studies. This indication is to 'rule-in' patients for adjuvant therapy; therefore, specificity and PPV are key performance characteristics. In Zager et al (2018) and Greenhaw et al (2018), the specificities were 71% and 87% respectively while the PPV were 48% and 24%, respectively. The PPV suggests that the majority of patients identified as high-risk by the DecisionDx test would not develop metastasis and would be unnecessarily subjected to additional treatment. Greenhaw et al (2018) also reported that in 219 AJCC stage I patients, 201 had DecisionDx class 1 (low-risk) scores and 18 had DecisionDx class 2 (high-risk) scores. The only metastasis in stage I patients occurred in a patient with a DecisionDx class 1 score. Therefore, none of their stage I patients benefited from DecisionDx testing but 18 (8%) were incorrectly identified as high-risk for metastasis and could have received unnecessary treatment. There is no evidence that adjuvant therapy improves outcomes in these patients. Given that the evidence is insufficient to demonstrate test performance and there is no evidence that adjuvant therapy improves outcomes, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with stage I or II cutaneous melanoma with clinically negative sentinel node basins who are being considered for sentinel lymph node (SLN) biopsy who receive GEP with the DecisionDx-Melanoma test to determine whether to perform SLN biopsy, the evidence includes retrospective observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, resource utilization, and treatment-related morbidity. The DecisionDx-Melanoma test has 3 independent clinical validity studies that have reported 5-year RFS in AJCC stage I or II patients. Gerami et al (2015) reported RFS rates of 98% in DecisionDx class 1 (low-risk) without CIs, in AJCC stage I or II patients. Zager et al (2017) reported RFS rates of 96% (95% CI, 94% to 99%) for DecisionDx class 1 in patients with AJCC stage I disease; they also reported RFS rates of 74% (95% CI, 60% to 91%) for DecisionDx class 1 in patients with AJCC stage II disease. Although CIs were not available for the first study, RFS does not appear to be well-characterized as evidenced by the variation in estimates across studies. Zager et al (2017) also reported that in 56 patients who were DecisionDx class 1 (low-risk) but SLN biopsy-positive, 22 recurrences (39%) occurred over 5 years. If the DecisionDx test were used as a triage for SLN biopsy, these patients would not undergo SLN biopsy and would likely not receive adjuvant therapy, which has shown to be effective at prolonging time to recurrence in node-positive patients. Data on 5-year RFS is not available for the target population (Class 1A patients  $\leq 55$  years old who have tumors less than 2 mm deep [T1 to T2]) outside of the retrospective cohort that was used to identify the target population. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

#### Additional Information

Not applicable

#### Related Policies

- N/A

#### Benefit Application

Blue Shield of California Promise Health Plan is contracted with L.A. Care Health Plan for Los Angeles County and the Department of Health Care Services for San Diego County to provide Medi-Cal health benefits to its Medi-Cal recipients. In order to provide the best health care services and practices, Blue Shield of California Promise Health Plan has an extensive network of Medi-Cal primary care providers and specialists. Recognizing the rich diversity of its membership, our providers

are given training and educational materials to assist in understanding the health needs of their patients as it could be affected by a member's cultural heritage.

The benefit designs associated with the Blue Shield of California Promise Medi-Cal plans are described in the Member Handbook (also called Evidence of Coverage).

## Regulatory Status

### Cal. Health & Safety Code §1367.667, Insurance Code Section 10123.209, and Welfare and Institutions Code 14132.09

California laws that require insurers to cover biomarker testing for the diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition to guide treatment decisions, as prescribed.

### Clinical Laboratory Improvement Amendments (CLIA) and FDA Regulatory Overview

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The Pigmented Lesion Assay<sup>®</sup>, myPath Melanoma<sup>®</sup>, and DecisionDx-Melanoma<sup>®</sup> tests are available under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

## Health Equity Statement

Blue Shield of California Promise Health Plan's mission is to transform its health care delivery system into one that is worthy of families and friends. Blue Shield of California Promise Health Plan seeks to advance health equity in support of achieving Blue Shield of California Promise Health Plan's mission.

Blue Shield of California Promise Health Plan ensures all Covered Services are available and accessible to all members regardless of sex, race, color, religion, ancestry, national origin, ethnic group identification, age, mental disability, physical disability, medical condition, genetic information, marital status, gender, gender identity, or sexual orientation, or identification with any other persons or groups defined in Penal Code section 422.56, and that all Covered Services are provided in a culturally and linguistically appropriate manner.

## Rationale

### Background

#### Cutaneous Melanoma

Cutaneous melanoma accounts for more than 90% of cases of melanoma.<sup>1</sup> For many decades, melanoma incidence was rapidly increasing in the U.S. However, recent estimates have suggested the rise may be slowing. In 2025, close to 105,000 new cases of melanoma are expected to be diagnosed, and more than 8400 people are expected to die of melanoma.<sup>2</sup>

### Risk Factors

Exposure to solar ultraviolet radiation is a major risk factor for melanoma. Most melanomas occur on the sun-exposed skin, particularly those areas most susceptible to sunburn. Likewise, features that are associated with an individual's sensitivity to sunlight, such as light skin pigmentation, red or blond hair, blue or green eyes, freckling tendency, and poor tanning ability are well-known risk factors for melanoma.<sup>3,4</sup> There is also a strong association between high total body nevus counts and melanoma.<sup>5</sup>

Several genes appear to contribute to melanoma predisposition such as tumor suppressor gene *CDKN2A*, melanocortin-1 receptor (*MCLR*) gene, and *BAP1* variants.<sup>6,7,8</sup> Individuals with either familial or sporadic melanoma have 2 to 3 times increased risk of developing a subsequent primary melanoma.<sup>9</sup> Several occupational exposures and lifestyle factors, such as body mass index and smoking, have been evaluated as possible risk factors for melanoma.<sup>10</sup>

### Gene Expression Profiling

Gene expression profiling (GEP) measures the activity of thousands of genes simultaneously and creates a snapshot of cellular function. Data for GEP are generated by several molecular technologies including DNA microarrays that measure activity relative to previously identified genes and RNA-Seq that directly sequences and quantifies RNA molecules. Clinical applications of GEP include disease diagnosis, disease classification, prediction of drug response, and prognosis.

### Literature Review

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

### Gene Expression Profiling to Guide Initial Biopsy Decisions

#### Clinical Context and Test Purpose

Primary care providers evaluate suspicious pigmented lesions to determine who should be referred to dermatology. Factors considered include both a patient's risk for melanoma as well as a visual examination of the lesion. The visual examination assesses whether the lesion has features suggestive of melanoma.

Criteria for features suggestive of melanoma have been developed. One checklist is the ABCDE checklist<sup>11</sup>:

- **A**symmetry
- **B**order irregularities
- **C**olor variegation
- **D**iameter  $\geq 6$  mm
- **E**volution

Another criterion commonly used is the "ugly duckling" sign.<sup>12</sup> An ugly duckling is a nevus that is obviously different from others in a given individual. Primary care providers generally have a low threshold for referral to dermatology.

Melanoma is difficult to diagnose based on visual examination, and the criterion standard for diagnosis is histopathology. There is a low threshold for excisional biopsy of suspicious lesions for histopathologic examination due to the procedure's ease and low risk as well as the high probability of missing melanoma. However, the yield of biopsy is fairly low. The number of biopsies performed to yield 1 melanoma diagnosis has been estimated to be about 15 for U.S. dermatologists.<sup>13</sup> Therefore, a test that could accurately identify those lesions not needing a biopsy (i.e., a rule-out test for biopsy) could be clinically useful.

The purpose of gene expression profiling (GEP) in patients who have suspicious pigmented lesions being considered for biopsy is to inform a decision about whether to biopsy.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with suspicious pigmented lesions being considered for referral for biopsy, specifically those lesions meeting 1 or more ABCDE criteria.

### ***Interventions***

The test being considered is the DermTech Pigmented Lesion Assay. The Pigmented Lesion Assay test measures expression of 6 genes (*PRAME*, *LINC00518*, *CMIP*, *B2M*, *ACTB*, *PPIA*). The *PRAME* (PReferentially expressed Antigen in MELanoma) gene encodes an antigen that is preferentially expressed in human melanomas, and that is not expressed in normal tissues (except testis).<sup>14</sup> *LINC00518* (Long Intergenic Non-protein Coding RNA518) is a regulatory RNA molecule. The other 4 genes provide normalization values.<sup>15</sup> The feasibility of a test like Pigmented Lesion Assay was first described in Wachsman et al (2011) and Gerami et al (2014).<sup>16,17</sup> and development of the specific Pigmented Lesion Assay test was described in Gerami et al (2017).<sup>18</sup>

The test is performed on skin samples of lesions at least 5 mm in diameter obtained via noninvasive, proprietary adhesive patch biopsies of a stratum corneum specimen. The test does not work on the palms of hands, soles of feet, nails, or mucous membranes, and it should not be used on bleeding or ulcerated lesions.<sup>15</sup>

The Pigmented Lesion Assay test report includes 2 results. The first result is called the Pigmented Lesion Assay MAGE (Melanoma Associated Gene Expression), which indicates low-risk (neither *PRAME* nor *LINC00518* expression was detected), moderate-risk (expression of either *PRAME* or *LINC00518* was detected), or high-risk (expression of both *PRAME* and *LINC00518* was detected). The second result is as an algorithmic Pigmented Lesion Assay score that ranges from 0 to 100, with higher scores indicating higher suspicion of malignant disease.<sup>15</sup>

It is not clear whether the Pigmented Lesion Assay test is meant to be used as a replacement, triage, or add-on test with respect to dermoscopy. The Pigmented Lesion Assay sample report states that for low-risk lesions, physicians should "consider surveillance," while for moderate- and high-risk lesions, physicians should "recommend a biopsy." It does not state whether lesions with negative results should be further evaluated with dermoscopy or other techniques to confirm the lesion should not be biopsied. Therefore, this evidence review evaluates the test as a replacement for dermoscopy. As mentioned previously, there is a low threshold for biopsy of suspicious lesions. As such, tests that can rule-out the need for biopsy could be useful and thus sensitivity and negative predictive value are the performance characteristics of most interest.

### ***Comparators***

After a referral from primary care to dermatology settings, dermatologists use visual examination as well as tools such as dermoscopy to make decisions regarding biopsy of suspicious lesions. A meta-analysis of 9 studies (8487 lesions with 375 melanomas) compared dermoscopy with visual examination alone for the diagnosis of melanoma; it reported that, for clinicians with training in dermoscopy, adding dermoscopy to visual examination increased the sensitivity from 71% to 90%. The specificity numerically increased from 80% to 90%, but the difference was not statistically significant.<sup>19</sup> Although dermoscopy is noninvasive and may aid in decision making regarding biopsy, it is only used by approximately 50% to 80% of dermatologists in the U.S. due to lack of training, interest, or time required for the examination.<sup>20,21</sup>

The reference standard for diagnosis of melanoma is histopathology.

### **Outcomes**

The beneficial outcomes of a true-positive test result are appropriate biopsy and diagnosis of melanoma. The beneficial outcome of a true-negative test result is potentially avoiding unnecessary biopsy.

The harmful outcome of a false-positive result is having an unnecessary biopsy. The harmful outcome of a false-negative result is a potential delay in diagnosis and treatment.

The timeframe of interest for calculating performance characteristics is time to biopsy result. Patients who forgo biopsy based on test results could miss or delay the diagnosis of cancer. A longer follow-up would be necessary to determine the effects on overall survival (OS).

### **Study Selection Criteria**

For the evaluation of clinical validity of the Pigmented Lesion Assay test, studies that meet the following eligibility criteria were considered:

- Reported on a validation cohort that was independent of the development cohort
- Reported on the accuracy of the marketed version of the technology
- Included a suitable reference standard (histopathology)
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Determining whether a test can guide biopsy decisions is not based only on its sensitivity and specificity, but also on how the accuracy of the existing pathway for making biopsy decisions is changed by the test. Therefore, the appropriate design for evaluating performance characteristics depends on the role of the new test in the pathway for making biopsy decisions. New tests may be used as replacements for existing tests, to triage who proceeds from existing tests or add-on tests after existing tests. For replacement tests, the diagnostic accuracy of both tests should be concurrently compared, preferably in a paired design (i.e., patients receive both tests), and all patients receive the reference standard. For a triage test, a paired design is also needed, with the reference standard being performed preferably on all patients but at least for all discordant results. For an add-on test, the included patients can be limited to those who were negative after existing tests with verification of the reference standard in patients who are positive on the new test.<sup>22</sup>

### **Review of Evidence**

#### **Observational Studies**

Studies were excluded from the evaluation of the clinical validity of the Pigmented Lesion Assay test because they reported results of the development cohort,<sup>17</sup> they did not use the marketed version of the test,<sup>16,17</sup> did not include the reference standard test on Pigmented Lesion Assay negative patients,<sup>23</sup> did not report relevant outcomes,<sup>24</sup> did not adequately describe the patient characteristics,<sup>25,26</sup> or did not adequately describe patient selection criteria.<sup>25,26</sup>

The validation cohort from the Gerami et al (2017) publication was included.<sup>18</sup> The study characteristics are described in Table 1. The report stated that included lesions were selected by dermatologists experienced in pigmented lesion management from 28 sites in the U.S., Europe, and Australia; therefore, the samples were likely not consecutive or random. Information regarding the previous testing was not provided. The flow of potential and included samples was not clear, and whether the samples were all independent or multiple samples from the same patient were not described. Diagnosis of melanoma was based on consensus among a primary reader and 3 expert dermatopathologists. The report did not state whether the histopathologic diagnosis was blinded to

the results of the Pigmented Lesion Assay test but did state the diagnosis was “routinely” assessed. Interpretation of the Pigmented Lesion Assay result does not depend on a reader, so it is blinded to histopathologic results. In 11% of cases originally selected, a consensus diagnosis was not reached, and these samples were not included in the training or validation cohorts. Dates of data collection were not reported. Sex and anatomic location of biopsy were reported, but other clinical characteristics (e.g., risk factors for melanoma, presenting symptoms) were not. Study results are shown in Table 2. The study training cohort included 157 samples with 80 melanomas and 77 non-melanomas. The study validation cohort included 398 samples with 87 melanomas and 311 non-melanomas. Study relevance, design, and conduct gaps are in Tables 3 and 4.

Van Sambeek et al (2024), Kaufmann et al (2024), and Skelsey et al (2024) evaluated the performance of the Pigmented Lesion Assay test in real-world clinical settings to glean further insight regarding the clinical validity and utility of the test.<sup>27,28,29</sup> The study characteristics are described in Table 1 and the test performances are reported in Table 2. Overall, the 3 observational studies published similar results for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) as reported in the literature. However, the studies have some major limitations (Table 3 and 4), including but not limited to, clinical context and study population characteristics not adequately described, no comparator used, limited number of follow-up visits, inadequate description of test administration, and no registration of the studies were reported.

**Table 1. Clinical Validity Study Characteristics of the Pigmented Lesion Assay Test for Diagnosing Melanoma**

Study	Study Population	Design	Reference Standard for Dx of Melanoma	Threshold Score for PLA Test	Timing of Reference and PLA Tests	Blinding of Assessors
Gerami et al (2017) <sup>18</sup>	<ul style="list-style-type: none"> <li>• Adults</li> <li>• Suspicious pigmented lesion <math>\geq 4</math> mm in diameter</li> <li>• Without obvious or suspicious nodular melanoma</li> <li>• 24% from extremities, 13% from the head and neck, 62% from the trunk</li> <li>• 55% of samples from men</li> <li>• Median age, 49 y (range, 19 to 97 y)</li> </ul>	Retrospective Not consecutive or random	Histopathology; consensus diagnosis	Quantitative PCR yielded an amplification curve and a measurable cycle threshold value Either <i>LINC00518</i> or <i>PRAME</i> detected	PLA patch before surgical biopsy; timing between the patch and surgical biopsy unclear	Not clear
Van Sambeek et al (2024) <sup>27</sup>	Adults with clinically suspicious lesions for melanoma	Retrospective	Histopathology; consensus diagnosis	Quantitative PCR yielded an amplification curve and a measurable cycle threshold value Either <i>LINC00518</i> or <i>PRAME</i> detected	Timing of reference or PLA tests is unclear	No blinding
Kaufmann et al (2024) <sup>28</sup>	Adults with clinically suspicious lesions for melanoma	Retrospective	Histopathology; consensus diagnosis	Quantitative PCR yielded an amplification curve and a measurable cycle threshold value	Timing of reference or PLA tests is unclear	No blinding

Study	Study Population	Design	Reference Standard for Dx of Melanoma	Threshold Score for PLA Test	Timing of Reference and PLA Tests	Blinding of Assessors
Skelsey et al (2024) <sup>29</sup>	Adults with clinically suspicious lesions for melanoma	Retrospective	Histopathology; consensus diagnosis	Quantitative PCR yielded an amplification curve and a measurable cycle threshold value Either <i>LINCO0518</i> or <i>PRAME</i> detected	Timing of reference or PLA tests is unclear	No blinding

Dx: diagnosis; PCR: polymerase chain reaction; PLA: Pigmented Lesion Assay.

**Table 2. Clinical Validity Study Results of the Pigmented Lesion Assay Test for Diagnosing Melanoma**

Study	Initial N	Final N	Excluded Samples	Melanoma Prevalence	Sensitivity <sup>b</sup>	Specificity <sup>b</sup>	PPV <sup>b</sup>	NPV <sup>b</sup>
Gerami et al (2017) <sup>18</sup>	398 <sup>a</sup>	398	Before allocation to training and validation cohorts, 11% of original samples excluded due to lack of consensus diagnosis	22%	91 (83 to 96)	69 (64 to 74)	45 (38 to 53) <sup>c</sup>	96 (93 to 98) <sup>c</sup>
Van Sambeek et al (2024) <sup>27</sup>	893	576	893 tests were used but only 576 were accompanied with at least 1 biopsy or follow-up visit	~6.25%	92 (84 to 100)	79.5 (76.2 to 82.9)	16.9 (11.8 to 24.3)	99.5 (99.1 to 100)
Kaufmann et al (2024) <sup>28</sup>	19,653	4461 <sup>d</sup>	Biopsy results and/or follow-up examinations were available for 5,096 lesions with 4461 having ≥ 6 months follow-up	NA	94.2 (91.3 to 96.3)	66.9 (65.5 to 68.4)	20.9 (19.0 to 22.9)	99.2 (98.8 to 99.5)
Skelsey et al (2024) <sup>e,29</sup>	4282	2197 <sup>d</sup>	Biopsy results and/or follow-up examinations were available for 4282 lesions with 2197 having ≥ 6 months follow-up	NA	97.2 <sup>c</sup>	86 <sup>c</sup>	22.5 <sup>c</sup>	99.9 <sup>c</sup>

NA: not available; NPV: negative predictive value; PPV: positive predictive value

<sup>a</sup> 398 samples were included in the validation cohort; the number of independent patients is unclear.

<sup>b</sup> Values are percentages with 95% confidence interval.

<sup>c</sup> Confidence intervals not provided in the report; calculated from data provided.

<sup>d</sup> Results are for lesions with ≥ 6 months follow-up.

<sup>e</sup> Results were combined for Fitzpatrick skin types and confidence intervals were not available.

**Table 3. Clinical Validity Study Relevance Limitations of the Pigmented Lesion Assay Test**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-Up <sup>e</sup>
Gerami et al (2017) <sup>18</sup>	3. Study population characteristics not		3. No comparison to dermoscopy	3. Predictive values were not reported but	

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-Up <sup>e</sup>
	adequately described			were calculated based on data provided	
Van Sambeek et al (2024) <sup>27</sup>	2. Clinical context is unclear 3. Study population characteristics not adequately described		3. No comparison to dermoscopy		1. Follow-up duration not sufficient with respect to natural history of disease
Kaufmann et al (2024) <sup>28</sup>	2. Clinical context is unclear 3. Study population characteristics not adequately described		3. No comparison to dermoscopy		1. Follow-up duration not sufficient with respect to natural history of disease
Skelsey et al (2024) <sup>29</sup>	2. Clinical context is unclear 3. Study population characteristics not adequately described		3. No comparison to dermoscopy		1. Follow-up duration not sufficient with respect to natural history of disease

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

<sup>c</sup> Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

<sup>d</sup> Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

<sup>e</sup> Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true-positives, true-negatives, false-positives, false-negatives cannot be determined).

**Table 4. Clinical Validity Study Design and Conduct Limitations of the Pigmented Lesion Assay Test**

Study	Selection <sup>a</sup>	Blinding <sup>b</sup>	Delivery of Test <sup>c</sup>	Selective Reporting <sup>d</sup>	Completeness of Follow-Up <sup>e</sup>	Statistical <sup>f</sup>
Gerami et al (2017) <sup>18</sup>	1,2. Not clear what criteria used to select samples, but it does not appear to have been random or consecutive	1. Blinding of histopathology readers not described	1. Patch biopsy administered before surgical biopsy but timing between procedures not described	1. No registration reported		
Van Sambeek et al (2024) <sup>27</sup>	2. Not random or consecutive	1. Blinding of histopathology readers not described	1. Patch biopsy administered and timing between procedures not described	1. No registration reported		2. Comparison to other tests not reported.
Kaufmann et al (2024) <sup>28</sup>	1,2. Not clear what criteria used to select samples, but it does not	1. Blinding of histopathology readers not described	1. Patch biopsy administered and timing between procedures not described	1. No registration reported		2. Comparison to other tests not reported.

Study	Selection <sup>a</sup>	Blinding <sup>b</sup>	Delivery of Test <sup>c</sup>	Selective Reporting <sup>d</sup>	Completeness of Follow-Up <sup>e</sup>	Statistical <sup>f</sup>
	appear to have been random or consecutive					
Skelsey et al (2024) <sup>29</sup>	1,2. Not clear what criteria used to select samples, but it does not appear to have been random or consecutive	1. Blinding of histopathology readers not described	1. Patch biopsy administered and timing between procedures not described	1. No registration reported		1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

<sup>b</sup> Blinding key: 1. Not blinded to results of reference or other comparator tests.

<sup>c</sup> Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

<sup>d</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>e</sup> Follow-Up key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

<sup>f</sup> Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

### Clinically Useful

A test is clinically useful if the results inform management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

No direct evidence of clinical utility was identified.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence.

A decision-impact study by Ferris et al (2017) assessed the potential impact of Pigmented Lesion Assay on physicians' biopsy decisions in patients.<sup>25</sup> Forty-five dermatologists evaluated 60 clinical and dermoscopic images of atypical pigmented lesions (8 melanoma, 52 nonmelanoma). In the first round, dermatologists did not have Pigmented Lesion Assay test results and, in the second round, dermatologists had access to Pigmented Lesion Assay test results with the order of cases being scrambled. The dermatologists were asked whether the lesions should be biopsied after each round. Therefore, the corresponding number of biopsy decisions should be 45×60×2=5400. Data were collected in 2014 and 2015. Results were reported for 4680 decisions with no description of the disposition of the remaining decisions. Of the 4680 reported decisions, 750 correct biopsy decisions were made without Pigmented Lesion Assay results while 1331 were made with Pigmented Lesion Assay results and 1590 incorrect biopsy decisions were made without Pigmented Lesion Assay results while 1009 incorrect biopsy decisions were made with Pigmented Lesion Assay results.

**Section Summary: Gene Expression Profiling to Guide Initial Biopsy Decisions**

Multiple high-quality studies are needed to establish the clinical validity of a test. The Pigmented Lesion Assay test has 1 clinical validity study with many methodologic and reporting limitations. Therefore, performance characteristics are not well-characterized. Also, the test has not been compared with dermoscopy, another tool frequently used to make biopsy decisions. There is no direct evidence of clinical utility. A chain of evidence for clinical utility cannot be constructed due to lack of robust evidence of clinical validity.

**Gene Expression Profiling for Diagnosing Lesions with Indeterminate Histopathology  
Clinical Context and Test Purpose**

The diagnosis of melanoma was described in the previous section. The diagnosis of melanoma is histopathologic and when the histopathologic diagnosis is straightforward, ancillary methods such as comparative genomic hybridization, fluorescence in situ hybridization (FISH), and gene expression profiling (GEP) are not recommended. Therefore, the usefulness of an ancillary test is its ability to predict biologic behavior (metastasis) of lesions that are indeterminate by histopathology.

The purpose of GEP in individuals whose melanocytic lesion is indeterminate after histopathology is to aid in the diagnosis of melanoma and decisions regarding treatment and surveillance.

The following PICO was used to select literature to inform this review.

***Populations***

The relevant population of interest is individuals whose melanocytic lesion is indeterminate based on clinical and histopathologic features.

***Interventions***

The test being considered is the Castle Bioscience myPath Melanoma test. The myPath test measures expression of 23 genes using quantitative reverse-transcription polymerase chain reaction. Fourteen genes are involved in melanoma pathogenesis and are grouped into 3 components related to cell differentiation, cell signaling, and the immune response, and 9 housekeeper genes are also included. The test is performed on 5 standard tissue sections from an existing formalin-fixed, paraffin-embedded biopsy specimen.

The myPath test report includes an algorithmic myPath score ranging from -16.7 to 11.1, with higher, positive scores indicating higher suspicion of malignant disease. The myPath report also classifies these scores: -16.7 to -2.1 are "benign"; -2.0 to -0.1 are "indeterminate"; and 0.0 to +11.1 are "malignant". The development of the test has been described by Clarke et al (2015).<sup>30</sup>

The myPath test is meant as an add-on test to standard histopathology. Studies have evaluated the performance characteristics of the test when histopathology is used as the reference standard,<sup>30,31,32</sup> but are not the focus of this evidence review given that the test's potential usefulness is in evaluation of indeterminate lesions.

No recommendations for treatment or surveillance are given on the report.

***Comparators***

The reference standard for diagnosis of melanoma is histopathology. However, in cases of indeterminate histopathology, long-term follow-up is needed to evaluate the clinical outcome, specifically metastasis.

Comparative genomic hybridization and FISH are also used to diagnose indeterminate lesions although neither has been fully validated. FISH has been evaluated as a tool to aid in the diagnosis of lesions that are indeterminate, following histopathology in 2 studies that included histologically

ambiguous lesions and a clinical, long-term follow-up. One study reported by Gaiser et al (2010) included 22 melanocytic lesions (12 indeterminate) followed for a mean of 65 months (range, 10 to 156 months) and reported a FISH sensitivity of 60% and a specificity of 50% for development of metastases during follow-up.<sup>33</sup> A second study, reported by Vergier et al (2011), included 90 indeterminate melanocytic lesions of which 69 had no recurrence for at least 5 years of follow-up (mean, 9 years; range, 5 to 19 years) and 21 lesions that exhibited metastases. The sensitivity and specificity rates of the histopathologic review combined with FISH for the clinical outcome were 76% and 90%, respectively.<sup>34</sup>

### **Outcomes**

The beneficial outcomes of a true-positive test result are a diagnosis of melanoma and corresponding appropriate treatment and surveillance. The beneficial outcome of a true-negative test result is avoiding unnecessary surgery.

The harmful outcome of a false-positive result is having an unnecessary surgery and surveillance. The harmful outcome of a false-negative result is a delay in diagnosis and treatment.

The National Comprehensive Cancer Network guidelines state that even in the presence of node metastasis, indeterminate neoplasms can demonstrate benign biologic behavior, making it difficult to define a fully malignant lesion and also states that events in the group of indeterminate lesions tend to occur late. Therefore, the guidelines suggest that long-term follow-up is necessary to validate a test for this purpose.

Recurrence and metastases can occur many years after the treatment of melanoma. In the 2 studies evaluating long-term outcomes of FISH (described above), the mean follow-up was approximately 5.5 and 9 years.<sup>33,34</sup> In Vergier et al (2011), metastases in the FISH-negative group generally occurred within 5 years.<sup>34</sup>

For this section of the review, at least 5 years of event-free follow-up is required to confirm negative tests. The event of interest is metastasis.

### **Study Selection Criteria**

For the evaluation of clinical validity of the myPath test, studies that meet the following eligibility criteria were considered:

- Reported on a validation cohort that was independent of the development cohort
- Reported on the accuracy of the marketed version of the technology
- Included a suitable reference standard (clinical outcome with at least 5 years of follow-up for negatives)
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Review of Evidence**

#### **Observational Studies**

Studies were excluded from the evaluation of the clinical validity of the myPath test because authors did not use the specified reference standard of long-term (at least 5 years) follow-up<sup>30,31,35,36,37,32,38,39</sup> and/or did not adequately describe patient characteristics.<sup>30</sup>

Two studies met inclusion criteria. Study characteristics are described in Table 5, and results in Table 6. Study relevance, design, and conduct limitations are in Tables 7 and 8.

The Ko et al (2017) clinical validity study met selection criteria.<sup>40</sup> The study characteristics are described in Table 5. In Ko et al (2017), archived melanocytic neoplasms were submitted for myPath testing from university clinics in the US and United Kingdom with additional samples acquired from Avaden BioSciences.<sup>40</sup> Stage I, II, and III primary cutaneous melanomas that produced distant metastases subsequent to the diagnosis and benign lesions with clinical follow-up and no evidence of recurrence of metastases were included. For benign samples, a disease-free time of at least 5 years was recommended. Information on the previous testing was not provided. It is not clear if any of the samples originally had indeterminate histopathology results. Dates of data collection were not reported. Sex, age, Breslow depth, and anatomic location were described; presenting symptoms were not reported. A total of 293 samples were submitted; of these, 53 did not meet inclusion criteria and 58 (24% of those tested) failed to produce a valid test score. An additional 7 samples with indeterminate results were excluded from the calculations of performance characteristics.

In a retrospective study using archived samples from a previous validation study, Clarke et al (2020) evaluated the performance of myPath in a population of diagnostically uncertain melanocytic neoplasms as compared with clinical outcomes.<sup>41</sup> Diagnostic uncertainty was defined as at least 1 dermatopathologist: selecting indeterminate as the diagnosis; selecting a diagnosis that was discordant with other dermatopathologists; indicating a need for additional diagnostic workup or indicating a preference for peer consultation before rendering a final diagnosis. Participating institutions were encouraged to submit lesions with at least 5 years of metastasis-free follow-up, but the length of follow-up was not an inclusion criterion. The median follow-up time for benign lesions was 74.9 months (interquartile range [IQR]: 57.9 to 114.7) and 69% (57/83) of cases had a follow-up of at least 5 years. The median time to metastasis for the malignant cases was 17 months (IQR: 10.3 to 37.6).

**Table 5. Clinical Validity Study Characteristics of the myPath Test for Predicting Metastasis**

Study	Study Population	Design	Reference Standard	Threshold Score for Positive myPath Test	Timing of Reference and myPath Tests	Blinding of Assessors
Ko et al (2017) <sup>40</sup>	<ul style="list-style-type: none"> <li>Primary cutaneous melanomas or benign melanocytic nevi</li> <li>Mean age, 53 y</li> <li>55% of samples from men</li> </ul>	Retrospective; not consecutive or randomly selected	Positive: malignant lesions that produced distant metastases Negative: Event-free follow-up, recommended 5 y (median, 6.2 y)	Scores from 0.0 to 11.1 (i.e., "malignant")	<ul style="list-style-type: none"> <li>Final clinical diagnosis established before myPath test</li> <li>Length of time between biopsy and myPath test unclear</li> </ul>	Yes
Clarke et al (2020) <sup>41</sup>	<ul style="list-style-type: none"> <li>Melanocytic neoplasms with diagnostic uncertainty</li> <li>Mean age 63.4 years, 32.7% female (malignant lesions), 42.4 years, 65.1% female (benign lesions)</li> </ul>	Retrospective; archived lesions obtained as part of a previous validation study. Case eligibility determined by clinical outcome; otherwise unselected.	Positive: malignant outcome defined as the detection of distant metastasis subsequent to initial biopsy. Lesions known to be malignant at initial biopsy excluded; otherwise no minimum follow-	Scores from 0.0 to 11.1 (i.e., "likely malignant")	Retrospective testing using archived samples.	Yes

Study	Study Population	Design	Reference Standard	Threshold Score for Positive myPath Test	Timing of Reference and myPath Tests	Blinding of Assessors
			up interval.  Negative: benign outcome was defined as absence of local recurrence or metastases throughout a protracted clinical follow-up period (5-year follow-up was not required).			

**Table 6. Clinical Validity Study Results of the myPath Test for Predicting Metastasis**

Study	Initial N	Final N	Excluded Samples	Melanoma Prevalence	Sensitivity <sup>a</sup>	Specificity <sup>a</sup>	PPV <sup>a</sup>	NPV <sup>a</sup>
Ko et al (2017) <sup>40</sup>	240	175	<ul style="list-style-type: none"> <li>58 failed to produce test result</li> <li>7 with indeterminate results</li> </ul>	54%	94 (87 to 98) <sup>b</sup>	96 (89 to 99) <sup>b</sup>	97 (91 to 99) <sup>b</sup>	93 (85 to 97) <sup>b</sup>
Clarke et al (2020) <sup>41</sup>	182	125	<ul style="list-style-type: none"> <li>56 not considered to be diagnostically uncertain; 1 missing slide</li> </ul>	44.1%	90.4 (79.0 to 96.8)	95.5 (87.3 to 99.1)	94.0 (83.8 to 97.9)	92.7 (84.6 to 96.7)

NPV: negative predictive value; PPV: positive predictive value.

<sup>a</sup> Values are percentages with 95% confidence interval.

<sup>b</sup> Confidence intervals not provided in the report; calculated from data provided.

**Table 7. Clinical Validity Study Relevance Limitations of the myPath Test**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-Up <sup>e</sup>
Ko et al (2017) <sup>40</sup>	4. Study population is not limited to lesions that are indeterminate following histopathology				None noted
Clarke et al (2020) <sup>41</sup>					1. Participating institutions were encouraged to submit lesions with at least 5 years of metastasis-free follow-up, but length of follow-up was not an inclusion criterion. 69% (57/83) of cases had 5-year follow-up

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

<sup>c</sup> Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3.

Not compared to other tests in use for same purpose.

<sup>d</sup> Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

<sup>e</sup> Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

**Table 8. Clinical Validity Study Design and Conduct Limitations of the myPath Test**

Study	Selection <sup>a</sup>	Blinding <sup>b</sup>	Delivery of Test <sup>c</sup>	Selective Reporting <sup>d</sup>	Completeness of Follow-Up <sup>e</sup>	Statistical <sup>f</sup>
Ko et al (2017) <sup>40</sup>	2. Samples not consecutive or random		1. Unclear how much time elapsed between biopsy and myPath test	1. No registration reported	2. More than 25% of samples tested did not produce results or produced indeterminate results	1. CIs for sensitivity and specificity not reported but were calculated based on data provided. NPV, PPV were not reported
Clarke et al (2020) <sup>41</sup>	2. Selection not random or consecutive; multiple exclusions			1. No registration reported	Unclear how many samples excluded prior to 182 identified as eligible	

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value.

<sup>a</sup> Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

<sup>b</sup> Blinding key: 1. Not blinded to results of reference or other comparator tests.

<sup>c</sup> Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

<sup>d</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>e</sup> Follow-Up key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

<sup>f</sup> Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

### Clinically Useful

A test is clinically useful if the results inform management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No direct evidence of clinical utility was identified.

### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Three decision-impact studies assessed the potential impact of myPath on physicians' treatment decisions in patients with diagnostically challenging lesions.<sup>42,43,44</sup> Given the lack of health outcomes, it is not known whether any treatment changes were clinically appropriate.

## Section Summary: Gene Expression Profiling for Diagnosing Lesions with Indeterminate Histopathology

Multiple high-quality studies are needed to establish the clinical validity of a test. The myPath test has 2 clinical validity studies including long-term follow-up for metastasis as the reference standard. In 1 study, it is not clear whether the study population included lesions that were indeterminate following histopathology. The second study focused on indeterminate lesions but had limitations including a retrospective design and less than 5-year follow-up in 31% of cases. Therefore, performance characteristics are not well-characterized. There is no direct evidence of clinical utility. A chain of evidence for clinical utility cannot be constructed due to the lack of robust evidence of clinical validity.

## Gene Expression Profiling to Guide Management Decisions in Melanoma Clinical Context and Test Purpose

Many treatments and surveillance decisions are determined by an individual's prognostic stage group based the American Joint Committee on Cancer (AJCC) tumor, node, metastasis staging system.<sup>45</sup> The prognostic groups are as follows: stage I, T1a through T2a primary melanomas without evidence of regional or distant metastases; stage II, T2b through T4b primary melanomas without evidence of lymphatic disease or distant metastases; stage III: pathologically documented involvement of regional lymph nodes or in transit or satellite metastases (N1 to N3); stage IV: distant metastases. Individuals may also undergo sentinel lymph node (SLN) biopsy to gain more definitive information about the status of the regional nodes.

Wide local excision is the definitive surgical treatment of melanoma. Following surgery, individuals with AJCC stage I or II (node-negative) melanoma do not generally receive adjuvant therapy. Individuals with higher risk melanoma receive adjuvant immunotherapy or targeted therapy. Ipilimumab has been shown to prolong recurrence-free survival (RFS) by approximately 25% compared with placebo at a median of 5.3 years in individuals with resected, stage III disease.<sup>46</sup> Nivolumab has been shown to further prolong survival compared with ipilimumab by approximately 35% at 18 months.<sup>47</sup> For patients who are *BRAF*V600 variant-positive with stage III melanoma, the combination of dabrafenib plus trametinib has been estimated to prolong relapse-free survival by approximately 50% over 3 years.<sup>48</sup>

Individuals with stage I and IIA disease should undergo an annual routine physical and dermatologic examination. These individuals typically do not receive surveillance imaging. Individuals with stage IIB to III melanoma may be managed with more frequent follow-up and imaging surveillance following therapy. However, follow-up strategies and intervals are not based on rigorous data, and opinions vary regarding appropriate strategies.

The purpose of GEP in individuals with melanoma is to identify low and high-risk individuals classified as stage I to III according to the AJCC criteria. Current guidelines do not recommend adjuvant therapy for AJCC stage I or II individuals following surgery. Individuals initially staged as I or II who have positive lymph nodes following SLN biopsy are then eligible to be treated with adjuvant therapy as stage III individuals.

At least 3 uses for the test have been suggested. One clinical validity study (described below), the authors stated that "high-risk individuals with stage I and II disease may benefit from adjuvant therapy and/or enhanced imaging protocols to allow for early detection of metastasis."<sup>49</sup> In another clinical validity study, the authors concluded that the test's "role in consideration of individuals for adjuvant therapy should be examined prospectively."<sup>50</sup> This use of the test would be as a replacement for SLN biopsy since SLN biopsy is currently used to identify individuals clinically diagnosed as stage I and II who have node involvement and are candidates for adjuvant therapy.

The manufacturer's website has suggested that physicians can use DecisionDx-Melanoma information to guide decisions regarding:

1. "Whether to perform a sentinel lymph node biopsy surgical procedure for eligible patients 55 years of age and older who have tumors less than 2 mm deep (T1 to T2)"
2. "Deciding what level of follow-up, imaging, and referrals are appropriate for any patient with a tumor at least 0.3 mm deep."

The use of the test reviewed for the Medicare population is to select individuals at low-risk of being lymph node-positive who can avoid an SLN biopsy (i.e., a triage test for SLN biopsy).

The following PICO was used to select literature to inform this review.

### ***Populations***

To select individuals for adjuvant therapy and/or enhanced surveillance, the relevant population of interest is individuals with AJCC stage I/II cutaneous melanoma.

To select individuals for enhanced surveillance and referrals, the relevant population of interest is individuals with AJCC stage I to III cutaneous melanoma.

To select individuals who can avoid SLN biopsy, the relevant population of interest is individuals with AJCC stage I or II cutaneous melanoma who are being considered for SLN biopsy. The manufacturer's website says the test is for 'eligible patients 55 years of age and older who have tumors less than 2 mm deep (T1 to T2)'

### ***Interventions***

The test being considered is the Castle Biosciences DecisionDx-Melanoma test. The DecisionDx test measures expression of 31 genes using quantitative reverse-transcription polymerase chain reaction.

The test includes 28 prognostic gene targets and 3 endogenous control genes. The test is performed on standard tissue sections from an existing formalin-fixed, paraffin-embedded biopsy or wide local excision specimen.

The development of the test was described in Gerami et al (2015).<sup>49</sup> To develop the DecisionDx-Melanoma gene panel, Gerami et al conducted a meta-analysis of published studies that identified differential gene expression in metastatic versus nonmetastatic primary cutaneous melanoma. Of 54 identified genes, investigators selected 20 for further polymerase chain reaction analysis based on chromosomal location. Five genes from Castle Biosciences' DecisionDx-UM gene panel were added based on analysis of metastatic and nonmetastatic primary cutaneous melanoma, and 2 probes of the *BRCA1*-associated protein 1 gene, *BAP1*, which has been associated with the metastatic potential of uveal melanoma, also were added. Finally, 4 genes with minimal variation in expression level between metastatic and nonmetastatic primary cutaneous melanoma were added as controls. Patients had a minimum follow-up of 5 years unless there was a well-documented metastatic event, including positive SLN biopsy. Information about treatments received was not provided.

The DecisionDx test report provides a 'class' which stratifies tumors as class 1 or class 2. According to the sample report available on the manufacturer's website: "The DecisionDx-Melanoma algorithm generates a value between 0 and 1 with a crossover point of 0.5. Subclassification (A or B) is based on proximity of this value to the crossover point."

### ***Comparators***

Treatment and surveillance recommendations are based on AJCC staging. SLN biopsy may be used to get more definitive information about the status of the regional nodes compared with a physical examination. The American Society of Clinical Oncology and National Comprehensive Cancer Network have similar but not identical recommendations regarding which patients should undergo SLN biopsy based on thickness and other high-risk features.

SLN biopsy has a low rate of complications; in the Sunbelt Melanoma Trial, a prospective multi-institutional study of SLN biopsy for melanoma reported by Wrightson et al (2003), less than 5% of the 2120 patients developed major or minor complications associated with SLN biopsy.<sup>51</sup>

Online tools are available to predict prognosis based on the AJCC guidelines. The original AJCC tool was developed by Soong et al (n.d.).<sup>52</sup> Callender et al (2012) incorporated SLN biopsy results into a revised tool (<http://www.melanomacalculator.com/>).<sup>53</sup>

### **Outcomes**

Regarding selecting patients for adjuvant therapy and/or enhanced surveillance in AJCC stage I or IIA individuals:

If the test is used to 'rule-in' a higher risk for recurrence or metastasis in AJCC stage I or IIA individuals, a negative DecisionDx (class 1) test result would not change outcomes. Per guidelines, the individuals would not receive adjuvant therapy or enhanced surveillance, just as without the DecisionDx test. A positive DecisionDx (class 2) test result would indicate that an individual might benefit from adjuvant therapy or enhanced surveillance. Therefore, the potential beneficial outcomes of a true positive result are additional treatment and surveillance and potentially prolonged survival. The potential harmful outcomes of a false-positive result are unnecessary adverse effects and burdens of adjuvant therapy enhanced surveillance.

Regarding individuals who would benefit from enhanced surveillance in AJCC stage IIB to III individuals:

If the test is used to "rule-in" risk for recurrence or metastasis in AJCC stage IIB to III patients, a positive DecisionDx (class 2) would indicate that an individual might benefit from enhanced surveillance. Therefore, the potential beneficial outcomes of a true positive result are additional surveillance and potentially prolonged survival. The potential harmful outcomes of a false-positive result are unnecessary adverse effects and burdens of enhanced surveillance.

If the test is used to 'rule-out' an increased risk for recurrence or metastasis in AJCC stage IIB to III individuals, a negative DecisionDx (class 1) test result would indicate that an individual might be able to avoid enhanced surveillance. Therefore, the potential beneficial outcomes of a true negative result are avoiding burdens of surveillance and potential overtreatment. The potential harmful outcomes of a false-negative result are reduced treatment and increase in mortality.

Regarding selecting AJCC stage I to IIA individuals who can avoid SLN biopsy:

For individuals meeting guideline-recommended criteria for SLN biopsy, a positive DecisionDx (class 2) test result would not change outcomes. The individuals would proceed to SLN biopsy, as they would have without the DecisionDx test, and treatment and imaging decisions would depend on SLN biopsy results. A negative DecisionDx (class 1) test result in individuals 55 years of age and older who have tumors less than 2 mm thick (T1 to T2) would indicate that an individual could avoid an SLN biopsy. Therefore, the potential beneficial outcomes of a true-negative result are avoidance of an SLN biopsy and related adverse effects and burdens. The potential harmful outcomes of a false-negative result are reduced time to recurrence due to not identifying node-positive individuals that would be eligible for beneficial adjuvant treatment and potentially reduced survival.

The risk of recurrence decreases over time but does not reach 0. In a study of 1568 individuals with stage I melanoma, Dicker et al (1999) found that 80% of the recurrences occurred within the first 3 years.<sup>54</sup> A prospective study by Garbe et al (2003) reported that, for stage I and II individuals, the risk of recurrence was low after 4.4 years.<sup>55</sup> Among 4731 individuals treated for more than 10 years at 1 institution, Faries et al (2013) found the majority of recurrences occurred in the first 5 years.<sup>56</sup> However, 7% of individuals experienced recurrence after 10 years (median, 16 years). Even among

stage I/II individuals, recurrence after 10 years occurred in 2% of individuals. Five-year RFS is the outcome and time-point of interest.

**Study Selection Criteria**

For the evaluation of clinical validity of the DecisionDx test, studies that meet the following eligibility criteria were considered:

- Reported on a validation cohort that was independent of the development cohort
- Reported on the accuracy of the marketed version of the technology
- Included a suitable reference standard (5-year RFS or 5-year metastasis-free survival [MFS])
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

**Review of Evidence**

**Systematic Review and Meta-Analysis**

Durgham et al (2024) collected data from 13 studies, comprising of 14,760 individuals, and conducted a meta-analysis to provide a comprehensive assessment of the current evidence of DecisionDx test's prognostic performance.<sup>57</sup> Critical appraisal of these studies using the Begg's test and Egger's regression test indicated an overall low risk of bias with the potential sources of bias attributed to study confounding, attrition, and participation. Relevant survival outcomes, based on the natural history of melanoma, for the GEP classes denoted by DecisionDx testing are displayed in Table 9 using a random effects estimates model to account for the confounding heterogeneity and variability of the studies used. The 5-year melanoma-specific survival (MSS) rate for the overall population was 97.5% (95% CI: 86.5 to 99.6). Additional survival-related outcomes (3-year overall survival, 3-year recurrence-free survival, 3-year distant metastasis-free survival, and 5-year MSS) were assessed and demonstrated better outcomes for Class 1 and 1A compared to Class 2 and 2B. Although this meta-analysis provides a consensus of the current literature for relevant survival outcomes of interest there are still some notable limitations of this review, including but not limited to, a small number of studies available for GEP class per outcome, heterogeneity among studies, lack of information on study treatments used during the studies, and the GEP test's categorization conflicts with the Melanoma Prevention Working Group's recommendations for GEP tests to be reported as continuous variables. Further evidence via randomized-control trials evaluating long-term outcomes of patients with GEP-informed testing is necessary to further define the possible role of the DecisionDx test in the management of patients with melanoma.

**Table 9. Summary of Random Effects Estimates for Survival-Related Outcomes in Durgham et al (2024)<sup>57</sup>**

Outcome	Number of Studies	Patients (N)	Random Effects Estimate (95% CI)	I2 (%)
Class 1A 5-year Recurrence-free survival %	3	2085	95.0 (91.8 to 97.0)	91.6
Class 1B 5-year Recurrence-free survival %	2	1647	83.3 (74.4 to 89.5)	96.8
Class 1IA 5-year Recurrence-free survival %	2	1647	82.3 (65.6 to 91.9)	98.9
Class 1IB 5-year Recurrence-free survival %	3	2085	50.5 (42.4 to 58.7)	93.4
Class 1A 5-year Distant Met-free survival %	3	2085	98.0 (96.1 to 98.9)	81.5
Class 1B 5-year Distant Met-free survival %	2	1647	87.1 (79.8–92.1)	96.1

Outcome	Number of Studies	Patients (N)	Random Effects Estimate (95% CI)	I2 (%)
Class IIA 5-year Distant Met-free survival %	2	1647	86.8 (72.2 to 94.4)	98.7
Class IIB 5-year Distant Met-free survival %	3	2085	62.4 (52.5 to 71.4)	95.5

The 31-GEP test classifies melanoma tumors into 4 risk classes: Class 1A (lowest risk), Class 1B and 2A (intermediate risk), and Class 2B (highest risk).

CI: confidence interval; I2: heterogeneity

### Observational Studies

Several papers were excluded from the evaluation of clinical validity. Hsueh et al (2017), Podlipnik et al (2019), Hsueh et al (2021), Kriza et al (2024), Guenther et al (2025), and Bailey et al (2023) were excluded from the evaluation of the clinical validity of the DecisionDx test because they did not report 5-year outcomes (median follow-up, 1.5 years, 2 years, 3.2 years, and 18 months, respectively).<sup>58,59,60,61,62</sup> Samples used in Gerami et al (2015)<sup>49</sup> and Ferris et al (2017)<sup>25</sup> appear to overlap with each other and will not be considered independent validation studies for inclusion in the tables. They are described briefly following the clinical validity tables. Data used in Gastman et al (2019) are stated to combine previous validation studies and included exploratory subgroup analysis.<sup>63,64,49,50</sup> Vetto et al (2019) included a retrospective cohort that was used to develop the model and is thus not eligible for inclusion, as well a prospective cohort without report of 5-year outcomes.<sup>65</sup> Marks et al (2019) describes the development of a cutpoint.<sup>66</sup>

Four independent clinical validity studies meeting eligibility criteria have been conducted. Characteristics and results are summarized in Tables 10 and 11 and briefly in the paragraphs that follow.

**Table 10. Clinical Validity Study Characteristics of the DecisionDx Test for Diagnosing Melanoma**

Study	Study Population	Design	Reference Standard / Outcome Measure	Threshold Score for Positive DecisionDx Test	Timing of Reference and DecisionDx Tests	Blinding of Assessors
Gerami et al (2015) <sup>49</sup> ; Validation subset	<ul style="list-style-type: none"> <li>Adults</li> <li>Stage I to IV cutaneous melanoma (87% stage I/II)</li> <li>At least 5 y of FU (median, 7.0 y)</li> <li>Median Breslow thickness, 0.8 mm (nonmetastasis) and 3.99 mm (metastasis)</li> <li>SLN positivity NR</li> </ul>	Retrospective Not consecutive or randomly selected	5-y RFS	Class 2 is high-risk. Risk threshold not provided	<ul style="list-style-type: none"> <li>Patient diagnosed between 1998 and 2009</li> <li>Timing of DecisionDx not described</li> </ul>	Yes
Zager et al (2018) <sup>50</sup>	<ul style="list-style-type: none"> <li>Stage I to III cutaneous melanoma (68% stage I/II)</li> <li>At least 5 y of FU (median, 7.5 y)</li> <li>Median Breslow thickness, 1.2 mm</li> <li>30% SLN positive</li> </ul>	Retrospective Not consecutive or randomly selected	5-y RFS	Class 2 is high-risk  Class 1: probability score 0 to 0.49  Class 2: probability	<ul style="list-style-type: none"> <li>Patients diagnosed between 2000 and 2014</li> <li>Timing of DecisionDx not described</li> </ul>	Yes

Study	Study Population	Design	Reference Standard / Outcome Measure	Threshold Score for Positive DecisionDx Test	Timing of Reference and DecisionDx Tests	Blinding of Assessors
				score 0.5 to 1		
Greenhaw et al (2018) <sup>67</sup>	<ul style="list-style-type: none"> <li>Patients who were treated for primary invasive CM of any Breslow depth within the last 5 years and had had GEP testing (86% stage I, 14% stage II)</li> <li>Mean follow-up of 23 months; only 20 patients had 5-year follow-up</li> </ul>	Retrospective Consecutive	5-y MFS	Commercial test cutoffs used	Institution offered DecisionDx testing to newly diagnosed and those treated within the previous 5 years	Yes
Keller et al (2019) <sup>68</sup>	<ul style="list-style-type: none"> <li>Patients had CM (91% stage I/II), opted for GEP testing and underwent SLN biopsy and wide excision of primary tumor</li> <li>Median follow-up time, 3.5 years</li> <li>Median Breslow thickness, 1.4 mm</li> <li>9% SLN positive</li> </ul>	Prospective	3-yr RFS (5-y RFS reported in a figure only)	Commercial test cutoffs used	<ul style="list-style-type: none"> <li>Patients diagnosed between 2013 and 2015</li> <li>GEP reported to be performed concurrently with SLN biopsy</li> </ul>	Yes

CM: cutaneous melanoma; FU: follow-up; GEP: gene expression profiling; MFS: metastasis-free survival; NR: not reported; RFS: recurrence-free survival; SLN: sentinel lymph node.

**Table 11. Clinical Validity Study Results of the DecisionDx Test for Diagnosing Melanoma**

Study	Initial / Final N	Excluded Samples	Events and Kaplan-Meier 5-Year RFS or MFS <sup>a</sup>		Sensitivity <sup>a</sup>	Specificity <sup>a</sup>	PPV <sup>a</sup>	NPV <sup>a</sup>
			Class 1	Class 2				
Gerami et al (2015) <sup>49</sup> ; Validation subset		Samples excluded if melanoma dx not confirmed, dissectible area not acceptable						
Overall	Unclear/104		4 events RFS=97 (NR)	31 events RFS=31 (NR) p<.001 vs class 1	89 (73 to 97) <sup>b</sup>	83 (72 to 91) <sup>b</sup>	72 (56 to 85) <sup>b</sup>	93 (84 to 98) <sup>b</sup>
AJCC stage I and II	Unclear/78		3 events RFS=98 (NR)	18 events RFS=37 (NR) p<.001 vs class 1	86 (64 to 97) <sup>b</sup>	84 (72 to 93) <sup>b</sup>	67 (46 to 83) <sup>b</sup>	94 (84 to 99) <sup>b</sup>
Zager et al (2018) <sup>50</sup>		Did not meet analytic quality control thresholds						

Study	Initial / Final N	Excluded Samples	Events and Kaplan-Meier 5-Year RFS or MFS <sup>a</sup>	Sensitivity <sup>a</sup>	Specificity <sup>a</sup>	PPV <sup>a</sup>	NPV <sup>a</sup>
Overall	601/523		42 events RFS=88 (85 to 92)	100 events RFS=52 (46 to 60)	70 (62 to 78)	71 (67 to 76)	48 (41 to 55) 87 (82 to 90)
AJCC stage I	Unclear/264		11 events RFS=96 (94 to 99)	6 events RFS=85 (74 to 97)	35 (14 to 62) <sup>b</sup>	87 (82 to 91) <sup>b</sup>	15 (6 to 31) <sup>b</sup> 95 (91 to 98) <sup>b</sup>
AJCC stage II	Unclear/93		9 events RFS=74 (60 to 91)	30 events RFS=55 (44 to 69)	77 (61 to 89) <sup>b</sup>	43 (29 to 57) <sup>b</sup>	49 (36 to 62) <sup>b</sup> 72 (53 to 86) <sup>b</sup>
Greenhaw et al (2018) <sup>67</sup>	256/256	None excluded but only 20 had 5-year follow-up	3 events MFS=93 (82 to 100)	8 events MFS=69 (52 to 90)	77 (46 to 94)	87 (82 to 91)	24 (13 to 40) 99 (96 to 100)
Keller et al (2019) <sup>68</sup>	159/174	15 patients had insufficient tumor for GEP testing	events unclear at year 5 RFS <sup>c</sup> ~ 97 (NR)	events unclear at year 5 RFS <sup>c</sup> ~ 40 (NR)	NR	NR	NR NR

AJCC: American Joint Committee on Cancer; Dx: diagnosis; GEP: gene expression profiling; MFS: metastasis-free survival; NPV: negative predictive value; NR: not reported; PPV: positive predictive value; RFS: recurrence-free survival

<sup>a</sup> Values are percentages with 95% confidence interval.

<sup>b</sup> Confidence intervals not provided in the report; calculated from data provided.

<sup>c</sup> RFS at 5 years not provided in text but estimated from a figure

The validation cohort in Gerami et al (2015) included patients with stage 0, I, II, III, or IV disease from 6 U.S. centers (N=104).<sup>49</sup> A complete disposition of samples received from the institutions and those included in the analysis was not provided. For 78 patients in the validation cohort with AJCC stage I or II cutaneous melanoma who had either a metastatic event or had more than 5 years of follow-up without metastasis, 5-year disease-free survival was 98% (confidence intervals [CIs] not reported) for DecisionDx class I patients and 37% for DecisionDx class II patients. The positive predictive value (PPV) and negative predictive value (NPV) were 67% and 94%, respectively. Confidence intervals for performance characteristics were calculated in Table 11 based on data provided. Reclassification of patients in AJCC stages to DecisionDx classes is shown in Table 12.

**Table 12. Reclassification of Patients Based on AJCC Stages to DecisionDx Classes in the Gerami Validation Cohort**

AJCC Stage	DecisionDx Class		
	Class 1 (Low-Risk), N (row %)	Class 2 (High-Risk), N (row %)	Total
0	0	0	
Total stage I	50 (89%) <sup>a</sup>	6 (11%)	56
IA	37	1	
IB	10	5	
Total stage II	10 (29%)	24 (71%)	34
IIA	5	8	
IIB	5	12	
IIC	0	4	
Total stage III	1 (8%)	11 (92%)	12
Total stage IV	0 (0%)	2 (100%)	2
Total	61	43	104

Adapted from Gerami et al (2015).<sup>49</sup>

AJCC: American Joint Committee on Cancer.

<sup>a</sup> The subclass for n=3 class 1 samples are not reported.

Zager et al (2018) reported results of a second clinical validity study including AJCC stage I, II, or III primary melanoma tumors from 16 U.S. sites.<sup>50</sup> The samples were independent of the other validation studies. Of the 601 cases submitted from the institutions, 523 were included in the analysis (357 stage I/II). The excluded samples did not meet pre- and post-analytic quality control thresholds. The SLN biopsy status was untested in 36% of the patients, negative in 34%, and positive in 30%. The report did not describe any adjuvant therapy that the patients received. Overall, 42 (13%) recurrence events occurred in DecisionDx class 1 patients and 100 (48%) recurrence events occurred in DecisionDx class 2 patients. The 5-year RFS estimated by Kaplan-Meier was 88% (95% CI, 85% to 92%) in class 1 and 52% (95% CI, 46% to 60%) in class 2. The reported sensitivity and specificity were 70% (95% CI, 62% to 78%) and 71% (95% CI, 67% to 76%), respectively, with a PPV of 48% (95% CI, 41% to 55%) and a NPV of 87% (95% CI, 82% to 90%). For comparison, the performance characteristics for 5-year RFS for SLN status among those with SLN biopsy were: sensitivity, 66% (95% CI, 57% to 74%); specificity, 65% (95% CI, 58% to 71%); PPV, 52% (95% CI, 44% to 60%); and NPV, 76% (95% CI, 69% to 82%). Estimates stratified by AJCC stage I or II are shown in Table 12. The reclassification of patients based on SLN biopsy status using DecisionDx classes is shown in Table 13. If DecisionDx were used as a triage test such that only class 2 received SLN biopsy, then 159 class 1 patients would not have undergone SLN biopsy. Of the 159 patients in class 1, 56 were SLN biopsy-positive and were therefore eligible for adjuvant therapy. It is not clear if the SLN biopsy-positive patients in this study received adjuvant therapy. Of the 56 patients who were DecisionDx class 1 and SLN biopsy-positive, 22 recurrence events occurred by 5 years.

Relevance, design, and conduct gaps are summarized in Tables 14 and 15.

**Table 13. Reclassification of Patients Based on SLN Biopsy Status to DecisionDx Classes**

SLN Biopsy	DecisionDx Class 1 (Low-Risk)			DecisionDx Class 2 (High-Risk)			Total
	n (%)	Events	5-Year RFS (95% CI), %	n (%)	Events	5-Year RFS (95% CI), %	
Negative	103 (65)	15	87 (81 to 94)	77 (43)	28	67 (57 to 79)	180
Positive	56 (35)	22	61 (49 to 76)	101 (57)	60	37 (28 to 49)	157
Total	159			178			337 <sup>a</sup>

Adapted from Zager et al (2017).<sup>50</sup>

CI: confidence interval; RFS: recurrence-free survival; SLN: sentinel lymph node.

<sup>a</sup> 337 patients had DecisionDx results and SLN biopsy results.

Greenhaw et al (2018) reported results of an independent study of the DecisionDx test using their institution’s melanoma registry and including patients who had been treated for cutaneous melanoma within the last 5 years and undergone DecisionDx testing.<sup>67</sup> Study characteristics and results were reported in the preceding Tables 10 and 11. Two-hundred fifty-six patients were tested; 84% were categorized as DecisionDx class 1 (low-risk) and 16% were DecisionDx class 2 (high-risk). Eighty-six percent (n=219) of tumors were AJCC stage I and 37 (14%) were AJCC stage II. None of the 18 stage I/class 2 tumors metastasized but 1 (0.5%) of 201 stage I/class 1 tumors metastasized. Ten (42%) of the stage II/class 2 tumors metastasized and 2 (15%) of the 13 stage II/class 1 tumors metastasized.

Keller et al (2019) reported results of a validity study including 159 patients (ages 26 to 88) diagnosed with melanoma in 2013 and 2015 who underwent SLN biopsy and concurrent GEP testing.<sup>68</sup> Study characteristics and results were reported in the preceding Tables 10 and 11. One hundred seventeen patients were classified as class 1 (91 subclass 1A and 26 subclass 1B) and 42 were classified as Class 2 (12 subclass 2A and 30 subclass 2B). Seventy-eight percent of the tumors were AJCC stage I, 13% were stage II, and 9% were stage III. Five-year RFS was reported only in a figure and sample sizes at year 5 and precision estimates were not included. There were 6 recurrent events (n=117) in class 1 patients by 3 years (3-year RFS, 97% [95% CI, 93 to 100]). There were 23 recurrent events (n=42) in class 2 patients (3-year RFS, 47% [95% CI, 34 to 65]). GEP class was significantly associated with RFS in multivariate analysis controlling for age, Breslow thickness, ulceration, and SLN biopsy results.

**Table 14. Clinical Validity Study Relevance Limitations of the DecisionDx Test**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Duration of Follow-Up <sup>e</sup>
Gerami et al (2015) <sup>49</sup> ; Validation subset	4. Study population includes AJCC stage III/IV lesions (13%), although analysis for only stage I/II was provided	1. Risk threshold for classification into class 1 or 2 not provided	3,4. Multivariate models included only control for AJCC stage. Reclassification not provided	2. Evidence-based treatment or surveillance pathway using the test is not described	
Zager et al (2018) <sup>50</sup>	4. Study population includes AJCC stage III lesions (32%), although analysis for only stage I/II was provided			2. Evidence-based treatment or surveillance pathway using the test is not described	
Greenhaw et al (2018) <sup>67</sup>			3. Not compared to other prediction tools	2. Evidence-based treatment or surveillance pathway using the test is not described	1. Only 20 patients had 5-year follow-up
Keller et al (2019) <sup>68</sup>				2. Evidence-based treatment or surveillance pathway using the test is not described	1. Unclear how many patients had 5 year follow-up

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

AJCC: American Joint Committee on Cancer.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

<sup>c</sup> Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

<sup>d</sup> Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

<sup>e</sup> Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true-positives, true-negatives, false-positives, false-negatives cannot be determined).

**Table 15. Clinical Validity Study Design and Conduct Limitations of the DecisionDx Test**

Study	Selection <sup>a</sup>	Blinding <sup>b</sup>	Delivery of Test <sup>c</sup>	Selective Reporting <sup>d</sup>	Completeness of Follow-Up <sup>e</sup>	Statistical <sup>f</sup>
Gerami et al (2015) <sup>49</sup> ; Validation subset	2. Not consecutive or random		1. Time between collection of biopsy and DecisionDx not described	1. No registration reported	1. No description of number of samples (if any) that failed to produce results or were indeterminate	1. CIs not reported but were calculated based on data provided
Zager et al (2018) <sup>50</sup>	2. Not consecutive or random		1. Time between collection of biopsy and	1. No registration reported	1. No description of number of samples (if any) that failed to	

Study	Selection <sup>a</sup>	Blinding <sup>b</sup>	Delivery of Test <sup>c</sup>	Selective Reporting <sup>d</sup>	Completeness of Follow-Up <sup>e</sup>	Statistical <sup>f</sup>
			DecisionDx not described		produce results or were indeterminate	
Greenhaw et al (2018) <sup>67</sup>			1. Some samples collected after treatment	1. No registration reported		
Keller et al (2019) <sup>68</sup>				1. No registration reported		1. Estimates and CIs at year 5 were not provided.

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

CI: confidence interval.

<sup>a</sup> Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

<sup>b</sup> Blinding key: 1. Not blinded to results of reference or other comparator tests.

<sup>c</sup> Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

<sup>d</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>e</sup> Follow-Up key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

<sup>f</sup> Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

In a subsequent analysis of patients with melanoma who had undergone SLN biopsy, Gerami et al (2015) compared prognostic classification by DecisionDx-Melanoma with biopsy results.<sup>69</sup> A total of 217 patients comprised a convenience sample from a database of 406 patients previously tested with DecisionDx-Melanoma. Patients who had undergone SLN biopsy appear to overlap with patients in Gerami et al (2015)<sup>69</sup> discussed previously. Most (73%) patients had a negative SLN biopsy, and 27% had a positive SLN biopsy. DecisionDx-Melanoma classified 76 (35%) tumors as low-risk (class I) and 141 (65%) tumors as high-risk (class II). Within the group of SLN biopsy-negative patients, the 5-year OS rate was 91% in class I patients and 55% in class II patients. Within the group of SLN biopsy-positive patients, the 5-year OS rate was 77% in class I patients and 57% in class II patients.

Ferris et al (2017) compared the accuracy of DecisionDx-Melanoma with the web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.<sup>70</sup> The study included 205 patients who appear to overlap with the patients in the second Gerami et al (2015) study described above. AJCC-predicted 5-year survival for each patient was categorized into low and high-risk based on both a 68% predicted 5-year survival and a 79% predicted 5-year survival. The 68% and 79% cutpoints were reported to correspond to 5-year survival in patients with stage IIA and IIB, respectively, although it is unclear whether those cutpoints were prespecified, whether they were based on internal or external estimates of risk, or whether they are commonly used in practice. The prognostic sensitivity and specificity for death (median follow-up, 7 years) of the Decision-Dx Melanoma were 78% and 69%, respectively (CIs not reported). The sensitivity and specificity for the AJCC calculator with the 79% cutpoint were 60% and 74%, respectively. The combination of the DecisionDx-Melanoma and AJCC tools had a sensitivity of 82% and specificity of 62%. The cross-classification for the DecisionDx-Melanoma and AJCC tools for 5-year OS is shown in Table 16.

Pazhava et al (2024) retrospectively analyzed electronic health records from patients with cutaneous melanoma who underwent GEP testing to evaluate the current clinical utility and performance of the DecisionDx test.<sup>71</sup> The study examined the prognostic performance of the GEP classifications using 2 survival outcomes: relapse-free survival (RFS) and melanoma-specific survival (MSS). The median follow-up for all survival endpoints was 38.7 months (~3 years), albeit there was significant variability in follow-up durations. Clinical utilization was assessed by determining if the GEP test influenced management decisions regarding a patient's melanoma diagnosis. Overall, the GEP classification only affected 18.5% of patients' management decisions with 2 cases forgoing SNL biopsy, 3 cases

referred to medical oncology, and 5 cases that had adjusted postdiagnosis surveillance, but ultimately these classifications did not significantly alter treatment decisions or led to better net health outcomes. Kaplan-Meier analysis indicated that survival curves for RFS and MSS between Class 1 versus Class 2 patients were not statistically different (RFS: HR = 1.12, p=.84, MSS: HR = 0.64, p=.76). However, patients with a positive SNL biopsy had worse RFS (50.0%, 95% CI [5.8 to 84.5]; 60.0%, 95% CI [36.6–77.2], respectively) and MSS (75.0%, 95% CI [12.8 to 96.1] 93.8%, 95% CI [63.2 to 99.1], respectively) rates compared to SNL biopsy negative patients, albeit not statistically significant.

**Table 16. Cross-Classification for the DecisionDx-Melanoma and AJCC Tool (79% Cutpoint) for 5-Year Overall Survival**

Risk Classification (DecisionDx-Melanoma vs AJCC)	N	No. of Events	5-Year Overall Survival, %
Low/low	105	9	96
Low/high	13	2	83
High/low	30	11	71
High/high	57	28	44

Adapted from Ferris et al (2017).<sup>25</sup>

AJCC: American Joint Committee on Cancer.

**Clinical Useful**

A test is clinically useful if the results inform management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

**Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

No direct evidence of clinical utility was identified.

**Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Decision-impact studies have been published reporting on the impact of DecisionDx on physicians’ management decisions.<sup>72,73,74,75,76,77,71</sup> Given the lack of established clinical validity and no reported long-term outcomes of the test used to select patients for active surveillance, it is not known whether any management changes were clinically appropriate.

For the proposed use of the test as a triage for SLN biopsy (identify patients who can avoid SLN biopsy), performance characteristics are not well-characterized.

For the proposed use of the test as a replacement for SLN biopsy (identify patients who are AJCC stage I/II who should receive adjuvant therapy), performance characteristics are also not well-characterized. In addition, an evidence-based management pathway would be needed to support the chain of evidence. The existing RCTs demonstrating that adjuvant therapy reduces recurrence included node-positive patients.

For the proposed use of the test to identify patients who are AJCC stage I/II who should receive enhanced surveillance, there is also a lack of evidence that imaging surveillance or increased frequency of surveillance improves outcomes in stage I/II patients. The National Comprehensive Cancer Network guidelines state that imaging surveillance is not recommended for stage I to IIA and can be ‘considered’ for IIB to IV but that there is an absence of meaningful data on the association of rigorous routine surveillance imaging with improved long-term outcome for stage IIB to IIC and the

recommendations regarding consideration of imaging surveillance remain controversial. While earlier detection of recurrence is thought to be beneficial because lower tumor burden and younger age are associated with improved treatment response and survival, this has not been proven and RCTs are needed to assess whether enhanced surveillance improves survival. The optimal frequency and duration of follow-up surveillance are not standardized and how the surveillance would be altered for DecisionDx class 2 patients has not been defined.

No evidence was identified that demonstrated that adjuvant therapy or increased surveillance improves net health outcomes in AJCC stage I or II patients who are DecisionDx class 2.

### **Section Summary: Gene Expression Profiling to Guide Management Decisions in Melanoma**

To use prognostic information for decision-making, performance characteristics should be consistent and precise. Two independent studies, using archived tumor specimens, have reported 5-year RFS in AJCC stage I or II patients.

If the test is to be used to select stage I and II patients for adjuvant therapy or enhanced surveillance then it should identify a group with high risk of recurrence. Gerami et al (2015) reported RFS rates of 37% for DecisionDx class 2 (high-risk) in patients in AJCC stage I and II patients. However, Zager et al (2018) reported RFS rates of 85% (95% CI, 74% to 97%) for DecisionDx class 2 patients in AJCC stage I and 55% (95% CI, 44% to 69%) for DecisionDx class 2 in AJCC stage II disease. In addition, to 'rule-in' patients for additional treatment or surveillance, the test should have specificity and PPV. In Zager et al (2018) and Greenhaw et al (2018) the specificities were 71% and 87%, respectively, while the PPV were only 48% and 24%, respectively. The low PPV suggests that the majority of patients identified as high-risk by the DecisionDx test would not develop metastasis and would be unnecessarily subjected to additional treatment or surveillance. Five-year RFS data are not available for the subgroup of patients for whom a 'rule-out' test would be relevant (class IIB through III).

If the test is to be used to select stage I and II patients who can avoid SLN biopsy, then it should identify a group who are eligible for SLN biopsy but have low risk of recurrence. Gerami et al (2015) reported RFS rates of 98% in DecisionDx class 1 (low-risk) without CIs in AJCC stage I or II patients. Zager et al (2018) reported RFS rates of 96% (95% CI, 94% to 99%) for DecisionDx class 1 in patients with AJCC stage I disease and RFS rates of 74% (95% CI, 60% to 91%) for DecisionDx class 1 in patients with AJCC stage II disease. Although CIs were not available for the first study, RFS does not appear to be well-characterized in either DecisionDx risk group as evidenced by the variation in estimates across studies. These studies do not report 5-year RFS in the specific population in which the manufacturer is suggesting utility for guiding SLN biopsy (i.e., Class 1A patients  $\leq 55$  years old who have tumors less than 2 mm deep [T1 to T2]). Data on 5-year RFS is not available for this target population outside of the Vetto (2019) retrospective cohort that was used to develop the target population.

Zager et al (2017) also reported that 56 of 159 (35%) patients who were DecisionDx class 1 (low-risk) were SLN biopsy-positive and in those patients 22 recurrences (39%) occurred over 5 years.<sup>50</sup> If the DecisionDx test were used as a triage for SLN biopsy, these patients would not undergo SLN biopsy and would likely not receive adjuvant therapy, which has shown to be effective at prolonging the time to recurrence in node-positive patients.

Greenhaw et al (2018) also reported that in 219 AJCC stage I patients, 201 had DecisionDx class 1 (low-risk) scores and 18 had DecisionDx class 2 (high-risk) scores. The only metastasis in stage I patients occurred in a patient with a DecisionDx class 1 score. Therefore, with respect to the proposed uses of identifying higher-risk patients that should receive adjuvant therapy or enhanced surveillance, none of their stage I patients benefited from DecisionDx testing but 18 (8%) were incorrectly identified as high-risk for metastasis and could have received unnecessary treatment or surveillance.

There is no direct evidence of clinical utility. A chain of evidence for clinical utility cannot be created due to lack of robust evidence of clinical validity and lack of evidence-based management pathway.

### Summary of Evidence

For individuals with suspicious pigmented lesions (based on ABCDE and/or ugly duckling criteria) being considered for biopsy who receive gene expression profiling (GEP) with the DermTech Pigmented Lesion Assay to determine which lesions should proceed to biopsy, the evidence includes observational studies. Relevant outcomes are overall survival, disease-specific survival, validity, and resource utilization. The Pigmented Lesion Assay has 4 clinical validity studies with many methodologic and reporting limitations. Therefore, performance characteristics are not well-characterized. Also, the test has not been compared with dermoscopy, another tool frequently used to make biopsy decisions. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have melanocytic lesions with indeterminate histopathologic features who receive GEP with the myPath Melanoma test added to histopathology to aid in the diagnosis of melanoma, the evidence includes observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, and treatment-related morbidity. The myPath test has 2 clinical validity studies including long-term follow-up for metastasis as the reference standard. In 1 study, it is not clear whether the study population included lesions that were indeterminate following histopathology. The second study focused on indeterminate lesions but had limitations including a retrospective design and less than 5-year follow-up in 31% of cases. Therefore, performance characteristics are not well-characterized. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with American Joint Committee on Cancer (AJCC) stage I to III cutaneous melanoma who receive GEP with the DecisionDx-Melanoma test to inform management decisions regarding surveillance, the evidence includes retrospective and prospective observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, resource utilization, and treatment-related morbidity. The DecisionDx-Melanoma test has 3 independent clinical validity studies that have reported 5-year recurrence-free survival (RFS) in AJCC stage I or II patients. Gerami et al (2015) reported RFS rates of 37% for DecisionDx class 2 (high-risk) in patients in AJCC stage I and II patients combined. Zager et al (2018) reported RFS rates of 85% (95% confidence interval [CI], 74% to 97%) for DecisionDx class 2 patients in AJCC stage I and 55% (95% CI, 44% to 69%) for DecisionDx class 2 in AJCC stage II disease. The RFS does not appear to be well-characterized as evidenced by the variation in estimates across studies. This indication is to 'rule-in' patients for enhanced surveillance; therefore, specificity and positive predictive value (PPV) are key performance characteristics. In Zager et al (2018) and Greenhaw et al (2018) the specificities were 71% and 87%, respectively, while the PPV were 48% and 24%, respectively. The PPV suggests that the majority of patients identified as high-risk by the DecisionDx test would not develop metastasis and would be unnecessarily subjected to additional surveillance. Greenhaw et al (2018) also reported that in 219 AJCC stage I patients, 201 had DecisionDx class 1 (low-risk) scores and 18 had DecisionDx class 2 (high-risk) scores. The only metastasis in stage I patients occurred in a patient with a DecisionDx class 1 score. Therefore none of their stage I patients benefited from DecisionDx testing but 18 (8%) were incorrectly identified as high-risk for metastasis and could have received unnecessary surveillance. Five-year RFS data are not available for the subgroup of patients for whom a 'rule-out' test would be relevant (class IIB through III). There is no evidence that changes to the frequency and methods for surveillance improve outcomes. Given that the evidence is insufficient to demonstrate test performance and there is no evidence that changes in surveillance improve outcomes, no inferences

can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with AJCC stage I or II cutaneous melanoma who receive GEP with the DecisionDx-Melanoma test to inform management decisions regarding adjuvant therapy, the evidence includes retrospective and prospective observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, resource utilization and treatment-related morbidity. The DecisionDx-Melanoma test has 3 independent clinical validity studies that have reported 5-year RFS in AJCC stage I or II patients. Gerami et al (2015) reported RFS rates of 37% for DecisionDx class 2 (high-risk) in patients in AJCC stage I and II patients combined. Zager et al (2018) reported RFS rates of 85% (95% CI, 74% to 97%) for DecisionDx class 2 patients in AJCC stage I and 55% (95% CI, 44% to 69%) for DecisionDx class 2 in AJCC stage II disease. RFS does not appear to be well-characterized as evidenced by the variation in estimates across studies. This indication is to 'rule-in' patients for adjuvant therapy; therefore, specificity and PPV are key performance characteristics. In Zager et al (2018) and Greenhaw et al (2018), the specificities were 71% and 87% respectively while the PPV were 48% and 24%, respectively. The PPV suggests that the majority of patients identified as high-risk by the DecisionDx test would not develop metastasis and would be unnecessarily subjected to additional treatment. Greenhaw et al (2018) also reported that in 219 AJCC stage I patients, 201 had DecisionDx class 1 (low-risk) scores and 18 had DecisionDx class 2 (high-risk) scores. The only metastasis in stage I patients occurred in a patient with a DecisionDx class 1 score. Therefore none of their stage I patients benefited from DecisionDx testing but 18 (8%) were incorrectly identified as high-risk for metastasis and could have received unnecessary treatment. There is no evidence that adjuvant therapy improves outcomes in these patients. Given that the evidence is insufficient to demonstrate test performance and there is no evidence that adjuvant therapy improves outcomes, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with stage I or II cutaneous melanoma with clinically negative sentinel node basins who are being considered for sentinel lymph node (SLN) biopsy who receive GEP with the DecisionDx-Melanoma test to determine whether to perform SLN biopsy, the evidence includes retrospective observational studies. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, resource utilization, and treatment-related morbidity. The DecisionDx-Melanoma test has 3 independent clinical validity studies that have reported 5-year RFS in AJCC stage I or II patients. Gerami et al (2015) reported RFS rates of 98% in DecisionDx class 1 (low-risk) without CIs, in AJCC stage I or II patients. Zager et al (2017) reported RFS rates of 96% (95% CI, 94% to 99%) for DecisionDx class 1 in patients with AJCC stage I disease; they also reported RFS rates of 74% (95% CI, 60% to 91%) for DecisionDx class 1 in patients with AJCC stage II disease. Although CIs were not available for the first study, RFS does not appear to be well-characterized as evidenced by the variation in estimates across studies. Zager et al (2017) also reported that in 56 patients who were DecisionDx class 1 (low-risk) but SLN biopsy-positive, 22 recurrences (39%) occurred over 5 years. If the DecisionDx test were used as a triage for SLN biopsy, these patients would not undergo SLN biopsy and would likely not receive adjuvant therapy, which has shown to be effective at prolonging time to recurrence in node-positive patients. Data on 5-year RFS is not available for the target population (Class 1A patients  $\leq$  55 years old who have tumors less than 2 mm deep [T1 to T2]) outside of the retrospective cohort that was used to identify the target population. No direct evidence of clinical utility was identified. Given that the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility through a chain of evidence. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American Academy of Dermatology

In 2019, the American Academy of Dermatology published guidelines of care for the management of primary cutaneous melanoma.<sup>78</sup> The guidelines state the following regarding gene expression profiling (GEP) tests:

- Regarding diagnostic GEP tests:
  - "Diagnostic molecular techniques are still largely investigative and may be appropriate as ancillary tests in equivocal melanocytic neoplasms, but they are not recommended for routine diagnostic use in CM [cutaneous melanoma]. These include comparative genomic hybridization, fluorescence in situ hybridization [FISH], gene expression profiling (GEP), and (potentially) next-generation sequencing."
  - "Ancillary diagnostic molecular techniques (e.g., CGH [comparative genomic hybridization], FISH, GEP) may be used for equivocal melanocytic neoplasms."
- Regarding prognostic GEP tests:
  - "...there is also insufficient evidence of benefit to recommend routine use of currently available prognostic molecular tests, including GEP, to provide more accurate prognosis beyond currently known clinicopathologic factors" (Strength of evidence: C, Level of evidence II/III)
  - "Going forward, GEP assays should be tested against all known histopathologic prognostic factors and contemporary eighth edition of AJCC [American Joint Committee on Cancer] CM staging to assess their additive value in prognostication."
  - "Routine molecular testing, including GEP, for prognostication is discouraged until better use criteria are defined. The application of molecular information for clinical management (e.g., sentinel lymph node eligibility, follow-up, and/or therapeutic choice) is not recommended outside of a clinical study or trial."

The American Academy of Dermatology's Choosing Wisely recommendation states that physicians not perform sentinel lymph node (SLN) biopsy or other diagnostic tests for the evaluation of early, thin melanoma because they do not improve survival.<sup>79</sup> The Academy noted that early, thin melanoma (melanoma in situ, T1a melanoma or T1b melanoma  $\leq 0.5$  mm) has a very low risk of the cancer spreading to the lymph nodes or other parts of the body and a 97% 5-year survival rate.

### National Comprehensive Cancer Network

The National Comprehensive Cancer Network guidelines (v.2.2025) for cutaneous melanoma made the following statements on use of GEP:<sup>80</sup>

The guidelines state the following regarding diagnostic testing for indeterminate melanocytic neoplasms following histopathology: "Melanocytic neoplasms of uncertain biologic potential present a unique challenge to pathologists and treating clinicians. Ancillary tests to differentiate benign from malignant melanocytic neoplasms include immunohistochemistry (IHC) and molecular testing via comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), gene expression profiling (GEP), single-nucleotide polymorphism (SNP) array, and next-generation sequencing (NGS). These tests may facilitate a more definitive diagnosis and guide therapy in cases that are diagnostically uncertain or controversial by histopathology. Ancillary tests should be used as adjuncts to clinical and expert dermatopathologic examination and therefore be interpreted within the context of these findings."

The guidelines state the following regarding prognostic testing:

- "Currently, there is insufficient evidence to support incorporation of current GEP tests into melanoma care. The use of gene expression profiling (GEP) according to specific AJCC-8 melanoma stage (before or after sentinel lymph node biopsy [SLNB]) requires further prospective investigation in large, contemporary data sets of unselected patients. Prognostic GEP tests to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures and are not recommended outside of the context of a clinical study or trial. Moreover, since there is a low probability of metastasis in stage I melanoma and a high proportion of false-positive results using these tests, GEP testing should not guide clinical decision-making in this subgroup. In addition, the likelihood of a positive SLNB may be informed by the use of multivariable nomograms/risk calculators. Ongoing prospective investigation will further inform the use of GEP tests for SLNB risk prediction."
- "Despite commercially available GEP tests being marketed to risk stratify cutaneous melanomas, current GEP platforms do not provide clinically actionable prognostic information when combined or compared with known clinicopathologic factors (e.g., sex, age, primary tumor location, thickness, ulceration, mitotic rate, lymphovascular invasion, microsatellites, and/or SLNB status). Furthermore, the clinical utility of these tests to inform treatment recommendations and improve health outcomes by prompting an intervention has not been established."
- "Various studies of prognostic GEP tests testing suggest their role as an independent predictor of worse outcomes. However, GEP studies to date have not demonstrated added benefit beyond comprehensive clinicopathologic (CP) variables, and it remains unclear whether available GEP tests are reliably predictive of outcome across the risk spectrum of melanoma. Validation studies on prospectively collected, independent cohorts (similar to those performed in breast cancer) are necessary to define the clinical utility of molecular prognostic GEP testing as an adjunct to AJCC staging and other known prognostically significant CP variables or as part of the multidisciplinary decision-making process to guide surveillance imaging, SLNB, and adjuvant therapy."
- "Existing and emerging GEP tests and other molecular techniques (i.e., circulating tumor DNA tests) should be prospectively compared to determine their clinical utility, including with no-cost, contemporary models that incorporate readily available CP variables. Prospective study of the utility of predictive GEP for SLNB risk, in conjunction with well-established CP factors, is ongoing."

### National Society for Cutaneous Medicine

In 2019, the National Society for Cutaneous Medicine published appropriate use criteria for the integration of diagnostic and prognostic GEP assays for management of cutaneous melanoma.<sup>81</sup> The criteria were developed with "unrestricted educational grants from related companies involved with these technologies". The majority of the panel members were consultants or advisors for Castle BioSciences or Myriad. The criteria were consensus-based using a modified Delphi approach. Numerous recommendations were made for each of the tests reviewed here. Some of the recommendations are as follows:

- Using Pigmented Lesion Assay test for patients with atypical lesions requiring assessment beyond visual inspection to help in selection for biopsy (B = Inconsistent or limited quality patient-oriented evidence)
- Using myPath for differentiation of a nevus from melanoma in an adult patient when the morphologic findings are ambiguous by light microscopic parameters (A = Consistent, good-quality patient-oriented evidence)
- Using DecisionDx by integrating results into the decision to adjust follow up regimens or to assess need for imaging (B = Inconsistent or limited quality patient-oriented evidence)
- Using DecisionDx by integrating results into subsequent management of patients:
  - Who are sentinel node negative (A = Consistent, good-quality patient-oriented evidence)

- Who are in AJCC “low risk” categories: (Thin (<1mm), Stage I to IIA, SLNBx-) (B= Inconsistent or limited quality patient-oriented evidence)
- Using DecisionDx by integrating 3I-GEP results as a criteria for inclusion in a chemotherapy regimen (C = Consensus, disease-oriented evidence, usual practice, expert opinion, or case series)

### U.S. Preventive Services Task Force Recommendations

Not applicable.

### Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Local coverage guidance for California is provided by the Molecular Diagnostic Services Program (MoIDx) in the documents [MoIDx: Molecular Assays for the Diagnosis of Cutaneous Melanoma](#) and [MoIDx: Melanoma Risk Stratification Molecular Testing](#), and their associated [Billing and Coding: MoIDx: Molecular Assays for the Diagnosis of Cutaneous Melanoma](#) and [Billing and Coding: MoIDx: Melanoma Risk Stratification Molecular Testing](#).

With regard to gene expression testing for the evaluation of individuals with melanocytic lesions with indeterminate histopathologic features, MoIDx states that it will provide limited coverage for molecular deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) assays including myPath [0090U] and DecisionDx®-DiffDx™ [0314U] when ALL of the following clinical conditions are met:

- The test is ordered by a board-certified or board-eligible dermatopathologist
- The specimen is a primary (non-metastatic, non-re-excision specimen) cutaneous melanocytic neoplasm for which the diagnosis is equivocal/uncertain (i.e., clear distinction between benign or malignant cannot be achieved using clinical and/or histopathological features alone) despite the performance of standard-of-care test procedures and relevant ancillary tests (i.e., immunohistochemical stains)
- The specimen includes an area representative of the lesion or portion of the lesion that is suspicious for malignancy
- The patient may be subjected to additional intervention, such as re-excision and/or sentinel lymph node biopsy, as a result of the diagnostic uncertainty
- The patient has not been tested with the same or similar assay for the same clinical lesion
- The test is validated for use in the intended-use population and is performed according to its stated intended-use
- The test demonstrates Analytical and Clinical Validity (AV and CV) and Clinical Utility (CU) and undergoes a technical assessment (TA) by MoIDx® to demonstrate compliance of the service with this policy

MoIDx: Molecular Assays for the Diagnosis of Cutaneous Melanoma (L39373):

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39373>

Billing and Coding: MoIDx: Molecular Assays for the Diagnosis of Cutaneous Melanoma (A59179):

<https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=59179&ver=9>

With regard to gene expression testing for risk stratification of cutaneous melanoma, MoIDx states tests, including DecisionDx®-Melanoma [81529] and Merlin™ [0578U] are covered when ALL of the following are true:

1. The patient has a personal history of melanoma AND:
  - a. Either
    - i. Has Stage T1b and above OR
    - ii. Has T1a with documented concern about adequacy of microstaging

- b. Is undergoing workup or being evaluated for treatment, AND
  - c. Does not have metastatic disease AND
  - d. Presumed risk for a positive Sentinel Lymph Node Biopsy (SLNB) based on clinical, histological, or other information is >5% AND
  - e. Has a disease stage, grade, and Breslow thickness (or other qualifying conditions) within the intended use of the test
2. The TEST has demonstrated, as part of a Technical Assessment:
- a. Clinical validity of analytes tested in predicting metastatic disease (or absence of metastatic disease) in peer-reviewed scientific literature
  - b. Utility beyond clinical, histological, and radiographical factors in the ability to accurately stratify patients into risk groups to manage patient care, such by precluding unnecessary sentinel lymph node biopsies
  - c. Appropriate analytical validity
  - d. Performance characteristics equivalent or superior to other covered, similar tests

MoIDX: Melanoma Risk Stratification Molecular Testing (L37750)

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37750&ver=31&keywordtype=starts&keyword=melanoma&bc=0>

Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing (A57268)

<https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57268&ver=20&keywordtype=starts&keyword=Billing%20and%20Coding%3A%20MoIDX%3A%20Melanoma%20Risk%20Stratification%20Molecular%20Testin&bc=0>

### Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in March 2025 did not identify any ongoing or unpublished trials that would likely influence this review.

## References

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer*. Oct 15 1998; 83(8): 1664-78. PMID 9781962
2. Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. *CA Cancer J Clin*. 2025; 75(1): 10-45. PMID 39817679
3. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. *N Engl J Med*. Apr 29 1999; 340(17): 1341-8. PMID 10219070
4. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. *Eur J Cancer*. Sep 2005; 41(14): 2040-59. PMID 16125929
5. Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. *Eur J Cancer*. Nov 2009; 45(17): 3054-63. PMID 19545997
6. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. *J Med Genet*. Feb 2007; 44(2): 99-106. PMID 16905682
7. Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al. Human Determinants and the Role of Melanocortin-1 Receptor Variants in Melanoma Risk Independent of UV Radiation Exposure. *JAMA Dermatol*. Jul 01 2016; 152(7): 776-82. PMID 27050141
8. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. *Nat Genet*. Aug 28 2011; 43(10): 1018-21. PMID 21874003

9. Chen T, Fallah M, Försti A, et al. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas. *JAMA Dermatol.* Jun 2015; 151(6): 607-15. PMID 25671687
10. Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. *Br J Dermatol.* Apr 2015; 172(4): 885-915. PMID 25354495
11. Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. *JAMA.* Dec 08 2004; 292(22): 2771-6. PMID 15585738
12. Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. *Arch Dermatol.* Jan 1998; 134(1): 103-4. PMID 9449921
13. Wilson RL, Yentzer BA, Isom SP, et al. How good are US dermatologists at discriminating skin cancers? A number-needed-to-treat analysis. *J Dermatolog Treat.* Feb 2012; 23(1): 65-9. PMID 21756146
14. National Center for Biotechnology Information. PRAME preferentially expressed antigen in melanoma. 2025; <https://www.ncbi.nlm.nih.gov/gene/23532>. Accessed March 24, 2025.
15. DermTech. Pigmented Lesion Assay: Non-invasive gene expression analysis of pigmented skin lesions. Performance and Development Notes. 2015; <https://dermtech.com/wp-content/uploads/2015/10/DermTech-PLA-White-Paper-080420152.pdf>. Accessed March 24, 2025.
16. Wachsman W, Morhenn V, Palmer T, et al. Noninvasive genomic detection of melanoma. *Br J Dermatol.* Apr 2011; 164(4): 797-806. PMID 21294715
17. Gerami P, Alsobrook JP, Palmer TJ, et al. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin. *J Am Acad Dermatol.* Aug 2014; 71(2): 237-44. PMID 24906614
18. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. *J Am Acad Dermatol.* Jan 2017; 76(1): 114-120.e2. PMID 27707590
19. Vestergaard ME, Macaskill P, Holt PE, et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. *Br J Dermatol.* Sep 2008; 159(3): 669-76. PMID 18616769
20. Murzaku EC, Hayan S, Rao BK. Methods and rates of dermoscopy usage: a cross-sectional survey of US dermatologists stratified by years in practice. *J Am Acad Dermatol.* Aug 2014; 71(2): 393-5. PMID 25037790
21. Engasser HC, Warshaw EM. Dermoscopy use by US dermatologists: a cross-sectional survey. *J Am Acad Dermatol.* Sep 2010; 63(3): 412-9, 419.e1-2. PMID 20619490
22. Bossuyt PM, Irwig L, Craig J, et al. Comparative accuracy: assessing new tests against existing diagnostic pathways. *BMJ.* May 06 2006; 332(7549): 1089-92. PMID 16675820
23. Ferris LK, Gerami P, Skelsey MK, et al. Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. *Melanoma Res.* Oct 2018; 28(5): 478-482. PMID 30004988
24. Peck GL, Johnson SR, Matthews SW, et al. Genomic Analysis Aids in the Management of Dermoscopically Atypical Pigmented Lesions. *J Drugs Dermatol.* Sep 01 2024; 23(9): 717-723. PMID 39231084
25. Ferris LK, Jansen B, Ho J, et al. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. *JAMA Dermatol.* Jul 01 2017; 153(7): 675-680. PMID 28445578
26. Bass J, Hill H, Jaworsky C. Significant discordance in DermTech test results when paired with histopathology: Caveat emptor. *J Am Acad Dermatol.* Nov 2023; 89(5): 1039-1041. PMID 37549792
27. Van Sambeek S, Friedlander E, Patino WD. A Retrospective Review: Our Experience With an Adhesive-Based Pigmented Lesion Assay Used to Evaluate Cutaneous Lesions Suspicious for Melanoma. *Am J Dermatopathol.* Nov 01 2024; 46(11): 729-733. PMID 39141756
28. Kaufmann, M., Skelsey, M., Ferris, L., Walker, M., Rigby, A., Jansen, B. and Clarke, L. 2024. Real-World Performance of a Noninvasive Cutaneous Melanoma Rule-Out Test: A

- Multicenter U.S. Registry Study. *SKIN The Journal of Cutaneous Medicine*. 8, 3 (May 2024), 15281531. DOI:<https://doi.org/10.25251/skin.8.3.8>.
29. Skelsey MK, Loftis B, Kaufmann MD, et al. Clinical performance of a noninvasive melanoma rule-out test across Fitzpatrick skin types. *J Am Acad Dermatol*. Mar 2025; 92(3): 620-621. PMID 39549846
  30. Clarke LE, Warf MB, Flake DD, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. *J Cutan Pathol*. Apr 2015; 42(4): 244-52. PMID 25727210
  31. Clarke LE, Flake DD, Busam K, et al. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. *Cancer*. Feb 15 2017; 123(4): 617-628. PMID 27768230
  32. Reimann JDR, Salim S, Velazquez EF, et al. Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms. *Mod Pathol*. Nov 2018; 31(11): 1733-1743. PMID 29955141
  33. Gaiser T, Kutzner H, Palmedo G, et al. Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. *Mod Pathol*. Mar 2010; 23(3): 413-9. PMID 20081813
  34. Vergier B, Prochazkova-Carlotti M, de la Fouchardière A, et al. Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. *Mod Pathol*. May 2011; 24(5): 613-23. PMID 21151100
  35. Ko JS, Clarke LE, Minca EC, et al. Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions. *Hum Pathol*. Apr 2019; 86: 213-221. PMID 30566894
  36. Clarke LE, Pimentel JD, Zalaznick H, et al. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma. *Hum Pathol*. Dec 2017; 70: 113-120. PMID 29079183
  37. Minca EC, Al-Rohil RN, Wang M, et al. Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. *Mod Pathol*. Aug 2016; 29(8): 832-43. PMID 27174586
  38. Boothby-Shoemaker W, Guan L, Jones B, et al. Real world validation of an adjunctive gene expression-profiling assay for melanoma diagnosis and correlation with clinical outcomes at an academic center. *Hum Pathol*. Sep 2023; 139: 73-79. PMID 37423481
  39. Goldberg MS, Cockerell CJ, Rogers JH, et al. Appropriate Statistical Methods to Assess Cross-study Diagnostic 23-Gene Expression Profile Test Performance for Cutaneous Melanocytic Neoplasms. *Am J Dermatopathol*. Dec 01 2024; 46(12): 833-838. PMID 39141759
  40. Ko JS, Matharoo-Ball B, Billings SD, et al. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. *Cancer Epidemiol Biomarkers Prev*. Jul 2017; 26(7): 1107-1113. PMID 28377414
  41. Clarke LE, Mabey B, Flake DD, et al. Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. *Per Med*. Sep 2020; 17(5): 361-371. PMID 32915688
  42. Cockerell C, Tschen J, Billings SD, et al. The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions. *Per Med*. Mar 2017; 14(2): 123-130. PMID 28757886
  43. Cockerell CJ, Tschen J, Evans B, et al. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. *Medicine (Baltimore)*. Oct 2016; 95(40): e4887. PMID 27749545
  44. Witkowski A, Jarell AD, Ahmed KL, et al. A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management. *Melanoma Manag*. 2024; 11(1): MMT68. PMID 38812731
  45. Gershenwald JES, R.A.; Hess, K.R.; et al. *Melanoma of the Skin*. Chicago, IL: American Joint Committee on Cancer; 2017.
  46. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *N Engl J Med*. Nov 10 2016; 375(19): 1845-1855. PMID 27717298

47. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. Nov 09 2017; 377(19): 1824-1835. PMID 28891423
48. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med*. Nov 09 2017; 377(19): 1813-1823. PMID 28891408
49. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. *Clin Cancer Res*. Jan 01 2015; 21(1): 175-83. PMID 25564571
50. Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. *BMC Cancer*. Feb 05 2018; 18(1): 130. PMID 29402264
51. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. *Ann Surg Oncol*. Jul 2003; 10(6): 676-80. PMID 12839853
52. Soong SJ, Ding S, Coit DG, et al. AJCC: Individualized melanoma patient outcome prediction tools. n.d.; <https://www.melanomaprognosis.net/> Accessed March 21, 2024.
53. Callender GG, Gershenwald JE, Egger ME, et al. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. *J Am Coll Surg*. Apr 2012; 214(4): 608-17; discussion 617-9. PMID 22342785
54. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. *Br J Dermatol*. Feb 1999; 140(2): 249-54. PMID 10233217
55. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. *J Clin Oncol*. Feb 01 2003; 21(3): 520-9. PMID 12560444
56. Faries MB, Steen S, Ye X, et al. Late recurrence in melanoma: clinical implications of lost dormancy. *J Am Coll Surg*. Jul 2013; 217(1): 27-34; discussion 34-6. PMID 23643694
57. Durgham RA, Nassar SI, Gun R, et al. The Prognostic Value of the 31-Gene Expression Profile Test in Cutaneous Melanoma: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. Nov 04 2024; 16(21). PMID 39518150
58. Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. *J Hematol Oncol*. Aug 29 2017; 10(1): 152. PMID 28851416
59. Podlipnik S, Carrera C, Boada A, et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. *J Eur Acad Dermatol Venereol*. May 2019; 33(5): 857-862. PMID 30702163
60. Hsueh EC, DeBloom JR, Lee JH, et al. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. *JCO Precis Oncol*. 2021; 5. PMID 34036233
61. Guenther JM, Ward A, Martin BJ, et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. *World J Surg Oncol*. Jan 03 2025; 23(1): 5. PMID 39754143
62. Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. *JCO Precis Oncol*. Jun 2023; 7: e2300044. PMID 37384864
63. Gastman BR, Gerami P, Kurlay SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. *J Am Acad Dermatol*. Jan 2019; 80(1): 149-157.e4. PMID 30081113
64. Gastman BR, Zager JS, Messina JL, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. *Head Neck*. Apr 2019; 41(4): 871-879. PMID 30694001

65. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. *Future Oncol.* Apr 2019; 15(11): 1207-1217. PMID 30691297
66. Marks, Etan et al. Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. *SKIN The Journal of Cutaneous Medicine, [S.l.]*, July 2019, v. 3, n. 4, p. 239-249.
67. Greenhaw BN, Zitelli JA, Brodland DG. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test. *Dermatol Surg.* Dec 2018; 44(12): 1494-1500. PMID 29994951
68. Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. *Cancer Med.* May 2019; 8(5): 2205-2212. PMID 30950242
69. Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. *J Am Acad Dermatol.* May 2015; 72(5): 780-5.e3. PMID 25748297
70. Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. *J Am Acad Dermatol.* May 2017; 76(5): 818-825.e3. PMID 28110997
71. Pazhava A, Kim YH, Jing FZ, et al. 31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort. *Int J Dermatol.* Mar 2025; 64(3): 563-570. PMID 39154363
72. Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. *Curr Med Res Opin.* Sep 2016; 32(9): 1599-604. PMID 27210115
73. Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. *J Drugs Dermatol.* May 01 2017; 16(5): 428-431. PMID 28628677
74. Schuitevoerder D, Heath M, Cook RW, et al. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging. *J Drugs Dermatol.* Feb 01 2018; 17(2): 196-199. PMID 29462228
75. Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. *Skin.* 2018;2(2):111-121.
76. Hyams DM, Covington KR, Johnson CE, et al. Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. *Future Oncol.* Feb 2021; 17(5): 517-527. PMID 33021104
77. Dillon LD, McPhee M, Davidson RS, et al. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. *Curr Med Res Opin.* Aug 2022; 38(8): 1267-1274. PMID 35081854
78. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol.* Jan 2019; 80(1): 208-250. PMID 30392755
79. American Academy of Dermatology. Choosing Wisely. <https://www.aad.org/member/clinical-quality/clinical-care/wisely>. Accessed March 24, 2025.
80. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cutaneous Melanoma. Version 2.2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf). Accessed March 24, 2025.
81. Berman, et.al. Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. *SKIN.* 2019; 3(5):291-298.
82. Centers for Medicare & Medicaid Services. (2023, August 6). Local Coverage Determination (LCD): MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma (L39373). U.S.

- Department of Health & Human Services. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39373&ver=5>. Accessed December 12, 2025.
83. Centers for Medicare & Medicaid Services. (2025, June 26). Local Coverage Determination (LCD): MoIDX: Melanoma Risk Stratification Molecular Testing (L37750). U.S. Department of Health & Human Services. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37750&ver=31&keywordtype=starts&keyword=melanoma&bc=0>. Accessed December 19, 2025.
84. Centers for Medicare & Medicaid Services. (2023, August 6). Local Coverage Determination (LCD) Reference Article: Billing and Coding: MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma (A59179). U.S. Department of Health & Human Services. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59179&ver=9>. Accessed December 12, 2025.
85. Centers for Medicare & Medicaid Services. (2025, October 1). Local Coverage Determination (LCD) Reference Article: Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing (A57268). U.S. Department of Health & Human Services. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57268&ver=20&keywordtype=starts&keyword=Billing%20and%20Coding%3A%20MoIDX%3A%20Melanoma%20Risk%20Stratification%20Molecular%20Testin&bc=0>. Accessed December 19, 2025.
86. Department of Healthcare Services Provider Manual Guideline. TAR and Non-Standard Benefits List: Codes 0001M thru 0999U. Accessed January 15, 2026, from [https://mcweb.apps.prd.cammi.medi-cal.ca.gov/assets/AFECB45B-D2C9-46AD-93A8-5C614B0E79A5/tarandnoncd0.pdf?access\\_token=6UyVkJRRfByXTZEWlh8j8QaYyIPyP5ULO](https://mcweb.apps.prd.cammi.medi-cal.ca.gov/assets/AFECB45B-D2C9-46AD-93A8-5C614B0E79A5/tarandnoncd0.pdf?access_token=6UyVkJRRfByXTZEWlh8j8QaYyIPyP5ULO)
87. Department of Healthcare Services Provider Manual Guideline. TAR and Non-Standard Benefits List: Codes 80000 thru 89999. Accessed January 15, 2026, from [https://mcweb.apps.prd.cammi.medi-cal.ca.gov/assets/30EEEF3-9AF6-4388-B324-DEB87CA7CD81/tarandnoncd8.pdf?access\\_token=6UyVkJRRfByXTZEWlh8j8QaYyIPyP5ULO](https://mcweb.apps.prd.cammi.medi-cal.ca.gov/assets/30EEEF3-9AF6-4388-B324-DEB87CA7CD81/tarandnoncd8.pdf?access_token=6UyVkJRRfByXTZEWlh8j8QaYyIPyP5ULO)
88. Department of Healthcare Services All Plan Letter. All Plan Letter APL 22-010: Cancer Biomarker Testing. Accessed January 15, 2026, from <https://www.dhcs.ca.gov/formsandpubs/Documents/MMCDAPLsandPolicyLetters/APL2022/APL22-010.pdf>

## Documentation for Clinical Review

### Please provide the following documentation:

- History and physical and/or consultation notes including:
  - Clinical findings (i.e., pertinent symptoms and duration)
  - Comorbidities
  - Activity and functional limitations
  - Reason for procedure/test/device, when applicable
  - Pertinent past procedural and surgical history
  - Past and present diagnostic testing and results
  - Prior conservative treatments, duration, and response
  - Treatment plan (i.e., surgical intervention)
- Consultation and medical clearance report(s), when applicable
- Radiology report(s) and interpretation (i.e., MRI, CT, PET)
- Laboratory results
- Other pertinent multidisciplinary notes/reports: (i.e., psychological or psychiatric evaluation, physical therapy, multidisciplinary pain management), when applicable

### Post Service (in addition to the above, please include the following):

- Results/reports of tests performed
- Procedure report(s)

**Coding**

The list of codes in this Medical Policy is intended as a general reference and may not cover all codes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy.

Type	Code	Description
CPT®	0578U	Oncology (cutaneous melanoma), RNA, gene expression profiling by real-time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence <i>(Includes Merlin™ Test, SkylineDx USA, Inc)</i>
	0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) <i>(Includes Pigmented Lesion Assay (DermTech Melanoma Test), DERM-JES Holdings, LLC d/b/a DermTech, LLC)</i>
	0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, intermediate, malignant) <i>(Includes myPath® Melanoma, Castle Biosciences, Inc)</i>
	81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis
HCPCS	None	

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
03/01/2026	New policy.

**Definitions of Decision Determinations**

**Healthcare Services:** For the purpose of this Medical Policy, Healthcare Services means procedures, treatments, supplies, devices, and equipment.

**Medically Necessary or Medical Necessity** means reasonable and necessary services to protect life, to prevent significant illness or significant disability, or alleviate severe pain through the diagnosis or treatment of disease, illness, or injury, as required under W&I section 14059.5(a) and 22 CCR section 51303(a). Medically Necessary services must include services necessary to achieve age-appropriate growth and development, and attain, maintain, or regain functional capacity.

For Members less than 21 years of age, a service is Medically Necessary if it meets the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) standard of Medical Necessity set forth in 42 USC section 1396d(r)(5), as required by W&I sections 14059.5(b) and 14132(v). Without limitation, Medically Necessary services for Members less than 21 years of age include all services necessary to

achieve or maintain age-appropriate growth and development, attain, regain or maintain functional capacity, or improve, support, or maintain the Member's current health condition. Contractor must determine Medical Necessity on a case-by-case basis, taking into account the individual needs of the Child.

### Criteria Determining Experimental/Investigational Status

In making a determination that any procedure, treatment, therapy, drug, biological product, facility, equipment, device, or supply is "experimental or investigational" by the Plan, the Plan shall refer to evidence from the national medical community, which may include one or more of the following sources:

1. Evidence from national medical organizations, such as the National Centers of Health Service Research.
2. Peer-reviewed medical and scientific literature.
3. Publications from organizations, such as the American Medical Association (AMA).
4. Professionals, specialists, and experts.
5. Written protocols and consent forms used by the proposed treating facility or other facility administering substantially the same drug, device, or medical treatment.
6. An expert physician panel selected by one of two organizations, the Managed Care Ombudsman Program of the Medical Care Management Corporation or the Department of Managed Health Care.

## Feedback

Blue Shield of California Promise Health Plan is interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration. Our medical policies are available to view or download at [www.blueshieldca.com/en/bsp/providers](http://www.blueshieldca.com/en/bsp/providers).

For medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

Questions regarding the applicability of this policy should be directed to the Blue Shield of California Promise Health Plan Prior Authorization Department at (800) 468-9935, or the Complex Case Management Department at (855) 699-5557 (TTY 711) for San Diego County and (800) 605-2556 (TTY 711) for Los Angeles County or visit the provider portal at [www.blueshieldca.com/en/bsp/providers](http://www.blueshieldca.com/en/bsp/providers).

*Disclaimer: Blue Shield of California Promise Health Plan may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as member health services contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member health services contracts may differ in their benefits. Blue Shield of California Promise Health Plan reserves the right to review and update policies as appropriate.*